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SUMMARY 
CD4+Foxp3+ regulatory T cells (Treg) are essential for maintaining immune tolerance and play a critical 
role in the control of autoimmune responses. During actively induced Experimental Autoimmune 
Encephalomyelitis (EAE), an animal model for Multiple Sclerosis, Treg  accumulate in the central nervous 
system (CNS), paralleling the recovery from the disease. However, whether Treg are essential for 
recovery from EAE, as well their function in vivo, especially in the target organ CNS, remains to be 
elucidated. In the present study, the functional role of Treg cells in CNS autoimmunity was investigated, 
using combinations of transgenic mouse strains and EAE models, as well as intravital 2-photon imaging.  
To evaluate the role of Treg in recovery from EAE, selective and efficient depletion of Treg at the peak of 
EAE in mice immunized with myelin oligodentrocyte glycoprotein (MOG) was performed. Interestingly, 
ablation of Treg not only prevented recovery, but led to fatal disease. The severe exacerbation of the 
disease was characterized by enhanced numbers of IFNγ- and IL-17-producing effector T cells (Teff) in 
immunization-site draining lymph nodes (LN) and the CNS. In parallel, elevated numbers of macrophages 
were found in the CNS infiltrates of Treg-depleted mice, while lower frequency of regulatory (M2) 
macrophages was observed in LN. These findings suggest that Treg mediate recovery from EAE by 
controlling Teff and macrophage in LN or the CNS, or both. 
To visualize the function of Treg within the CNS during EAE, intravital 2-photon imaging was performed 
in the spinal cord meninges of MOG-immunized mice at different phases of the disease. Treg were 
significantly more motile and displayed shorter interactions with Teff and local APC at the onset, while 
they showed decreased motility and formed prolonged contacts with APC at the peak of EAE, indicating 
that Treg exhibit their suppressive function during this phase. In contrast, the motility of Teff and their 
contact duration with APC did not change drastically throughout the disease. Importantly, depletion of 
Treg at the peak of EAE resulted in decreased motility of Teff, although the duration and number of Teff-
APC contacts was not affected. Therefore, either prevention of stable Teff-APC contacts is not the 
suppression mechanism that Treg use in the CNS or Treg control the autoimmune response in the 
peripheral immune organs, rather than in the CNS. 
The role of Treg was also examined in a spontaneous EAE (sEAE) model, the spontaneous opticospinal 
EAE (OSE) mice, 50% of which develop sEAE. Intriguingly, no difference was observed in the frequency, 
antigen-specificity or suppressive capacity of Treg between affected and resistant OSE mice. 
Nonetheless, MOG-specific Treg appeared in strikingly high frequency in the CNS infiltrates of affected 
OSE mice already at the disease onset and persisted throughout the disease course. Furthermore, 
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depletion of Treg in OSE mice, starting before the onset of sEAE, increased the incidence, but not 
severity, of the disease. These observations indicate a protective role for Treg also in sEAE and point to 
the periphery as the site of Treg-mediated suppression.  
In summary, both the functional and imaging data presented in this thesis establish a definitive role for 
Treg in recovery from EAE. 
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ZUSAMMENFASSUNG 
CD4+Foxp3+ regulatorische T-Zellen (Treg-Zellen) sind ein wichtiger Bestandteil des Immunsystems, 
dienen sie doch der Aufrechterhaltung der Selbsttoleranz und somit der Vermeidung von 
Autoimmunerkrankungen. Im Krankheitsverlauf der aktiv induzierten experimentellen autoimmunen 
Enzephalomyelitis (EAE), einem Tiermodell der Multiplen Sklerose, kommt es zu einer Ansammlung von 
Treg-Zellen im zentralen Nervensystem (ZNS) und in Folge dessen zu einer Verbesserung der 
Krankheitssymptome. Jedoch ist die Funktion von Treg-Zellen in vivo (v.a. im ZNS), sowie der 
Zusammenhang von Treg-Zellen mit der Verbesserung der EAE-Symptome noch unklar. In der 
vorliegenden Arbeit wurde die Rolle der Treg-Zellen in einer ZNS-spezifischen Autoimmunerkrankung 
anhand transgener Mausstämme, verschiedenen Krankheitsmodellen, sowie intravitaler 2-Photonen 
Mikroskopie untersucht.  
Um den Einfluss der Treg-Zellen auf die Genesungsphase der EAE zu untersuchen, wurden Treg-Zellen 
am Höhepunkt der Erkrankung in Mäusen immunisiert mit Myelin Oligodendrozyten Glykoprotein (MOG) 
zielgerichtet und effektiv depletiert. Interessanterweise verhinderte die Depletion der Treg-Zellen nicht 
nur die Genesung, sondern hatte auch einen drastischen Fortschritt der EAE zur Folge. Die dramatische 
Verschlechterung der Krankheitssymptome war gekennzeichnet durch eine gesteigerte Anzahl an IFN-- 
und IL-17-produzierenden Effektor-T-Zellen (Teff) sowohl in den Lymphknoten als auch im ZNS. 
Außerdem wurden vermehrt Makrophagen in den ZNS-Infiltraten von Treg-depletierten Mäusen, sowie 
weniger regulatorische (M2) Makrophagen in den Lymphknoten nachgewiesen. Dies lässt vermuten, 
dass Treg-Zellen während der EAE eine Funktion in der Kontrolle von Teff-Zellen und Makrophagen in 
den Lymphknoten sowie dem ZNS übernehmen und dadurch den Verlauf der Krankheit positiv 
beeinflussen. 
Um die Funktion der Treg-Zellen im ZNS zu veranschaulichen, wurde intravitale 2-Photonen-Mikroskopie 
an den Gehirnhäuten des Rückenmarks von MOG-immunisierten Mäusen in verschiedenen Stadien der 
Krankheit durchgeführt. Zu Beginn der EAE zeigen Treg-Zellen eine höhere Mobilität sowie kürzere 
Interaktionen mit Teff-Zellen und lokalen Antigen-präsentierenden Zellen. Am Höhepunkt der Krankheit 
hingegen zeigen sie eine reduzierte Beweglichkeit. Ein zusätzlicher Hinweis auf eine supprimierende 
Rolle der Treg-Zellen ergibt sich aus längeren Kontakten mit Antigen-präsentierenden Zellen. Im 
Gegensatz dazu zeigten Teff-Zellen keine drastischen Veränderungen bezüglich ihrer Beweglichkeit bzw. 
Kontaktdauer mit Antigen-präsentierenden Zellen während verschiedenen Stadien der EAE. Mögliche 
Erklärungen wären zum einen, dass die Treg-vermittelte Suppression nicht über die verhinderte 
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Kontaktausbildung erfolgt, oder zum anderen, dass die Treg-vermittelte Kontrolle nicht wie vermutet im 
ZNS sondern in den peripheren Immunorganen stattfindet. 
Abschließend wurde die Rolle der Treg-Zellen zusätzlich in einem spontanen EAE (sEAE) Modell 
untersucht. Fünfzig Prozent der optikospinalen EAE (OSE) Mäuse entwickeln spontan EAE. 
Interessanterweise konnte kein Unterschied zwischen kranken und resistenten OSE Mäusen in Bezug auf 
die Frequenz, die Antigen-Spezifität oder die hemmende Wirkung der Treg-Zellen festgestellt werden. 
Bereits zu Beginn der Krankheit konnten große Mengen an MOG-spezifische Treg-Zellen in den ZNS-
Infiltraten von OSE Mäusen nachgewiesen werden. Eine Depletion der Treg-Zellen in OSE Mäusen vor 
Beginn der EAE hatte eine Erhöhung der Inzidenz-Rate, jedoch keine Verschlechterung der Krankheit zur 
Folge. Auch diese Ergebnisse weisen darauf hin, dass Treg-Zellen in OSE Mäuse ihre schützende Funktion 
in der Peripherie und weniger im ZNS entfalten.  
Zusammenfassend lässt sich anhand der funktionellen sowie Mikroskopie-Daten, die in der vorliegenden 
Arbeit vorgestellt wurden, eine Rolle der Treg-Zellen in der Erholungsphase der EAE vermuten. 
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INTRODUCTION 
 
1.1 Multiple Sclerosis 
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS), characterized by 
focal infiltration of lymphocytes that leads to inflammation, demyelination and axonal degeneration. 
First described by Jean-Martin Charcot in 1868, MS is today the most common inflammatory disorder of 
the CNS in the Western World, with approximately 500,000 affected individuals in Europe and more than 
2 million worldwide (Flachenecker and Stuke, 2008).  
MS symptoms include a variety of motor, sensory, visual and autonomic dysfunctions, depending on the 
location of demyelination sites and the size of neuronal damage. Hypoesthesia, muscle weakness and 
spasms, visual problems, fatigue, pain and cognitive impairment, as well as difficulty in moving, 
coordination and balance, are the main clinical features, few of which, however, are disease-specific. The 
diagnosis is supplemented by detection of abnormalities in white matter, using MRI (95% of the 
patients), and the presence of oligoclonal immunoglobulin bands in the cerebrospinal fluid after protein 
electrophoresis (90% of the patients) (Compston and Coles, 2008). After an initial acute episode, the 
majority of MS patients display a relapsing course (relapsing-remitting MS; RRMS), with not more than 1-
5 episodes per year. However, with time recovery from each attack becomes incomplete, leading 
eventually to accumulation of symptoms and a progressive disease phase (secondary progressive MS; 
SPMS). In fewer cases, the disease can be progressive from the beginning, lacking the relapsing phase 
(primary progressive MS; PPMS) (Compston and Coles, 2008) (Lassmann et al., 2007). In all MS types, the 
clinical course spans over several decades and the median time to death is approximately 30 years after 
the onset (Compston and Coles, 2008).  
The pathogenesis of MS is believed to be immune-mediated, although a neurodegenerative hypothesis 
cannot be entirely excluded. Under physiological conditions, the CNS is inaccessible to immune cells, due 
to the presence of the blood-brain barrier (BBB) and the lack of lymphatic vessels (Engelhardt and 
Ransohoff, 2005). However, during MS, massive number of immune cells manages to infiltrate the CNS 
causing inflammation, BBB disruption and demyelination. Inflammation is dominated by CD8+ T cells and 
activated macrophages or microglia and is accompanied by local secretion of proinflammatory cytokines 
and chemokines. Abundant demyelination is followed by axonal injury and degeneration, which cause 
the clinical symptoms. Although extensive remyelination occurs in 20% of MS patients, continuous 
demyelination and remyelination seems to exhaust the tissue repair capacity (Patrikios et al., 2006). 
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There is strong evidence supporting the autoimmune pathogenesis of MS, including the lesion 
domination by immune cell infiltrates, the presence of oligoclonal bands in the CSF, the association of 
HLA polymorphisms with disease susceptibility and the effect of T and B cell targeted immunotherapy 
(Wekerle, 2008). However, the antigen specificity of the immune response remains unresolved. 
 The etiology of MS, although not clear, is considered to be a combination of genetic and environmental 
factors. Despite the fact that MS is not regarded as a hereditary disease, monozygotic twins show 
concordance in 30% of the cases compared to 3-5% in first degree relatives. The main genetic risk factor 
is the major histocompatibility complex class II (HLA), as there is a strong and consistent association 
between MS and HLA DRB1*1501, DQA1*0102, and DQB1*0602 extended haplotype (Dyment et al., 
2004). Regarding the environmental factors, the global distribution of the disease indicates an increased 
risk of MS in higher geographic latitude. In agreement with the previous observation, correlation 
between MS and low sunlight exposure, as well as vitamin D deficiency, has been repeatedly reported 
(Handel et al., 2010; Marrie, 2004). Moreover, dietary habits, especially animal fat consumption, have 
been suggested been suggested to play a role in MS incidence (Schwarz and Leweling, 2005), which could 
possibly explain the rise in the disease prevalence in Japan since 1950, where diet has been shifted from 
traditional one to western style (Kira et al., 1999). Finally, several infectious agents, including Epstein-
Barr virus (EBV) and Chlamydia pneumoniae, have been associated with MS, but none has been 
definitively proven so far (Marrie, 2004). 
1.2 Experimental Autoimmune Encephalomyelitis 
Due to the limited access to ex vivo MS patient material (especially CNS biopsy), the disease 
heterogeneity and the need for investigating new therapeutic approaches, animal models for MS are 
required. Experimental Autoimmune Encephalomyelitis (EAE) is the most commonly used animal model 
for MS, providing an attractive setup of studying clinical, neuropathological and immunological aspects 
of MS, as well as of testing possible therapeutic treatments.  
EAE was first described in 1925, with rabbits developing paralysis and spinal cord inflammation after 
immunization with human spinal cord tissue (Koritschoner and Schweinburg, 1925). Few years later, CNS 
inflammation and demyelination was induced in rhesus monkeys by repeated injection of rabbit CNS 
tissue, in an attempt to study the neurological complications after rabies vaccination in humans (Rivers 
et al., 1933). The development of a mineral oil-based adjuvant by J. Freund (Freund and McDermott, 
1942), mixed with brain tissue, allowed EAE induction with only a single injection (Kabat et al., 1947). In 
the decades that followed, this technique was expanded in several animals (mice, rats, guinea pigs, 
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macaques, marmosets etc.). In the 1980’s, the autoimmune nature of this experimental model was 
proven, when EAE was induced by transfer of myelin-specific T cells to naïve syngeneic rats (Ben-Nun et 
al., 1981). Murine EAE models were first described in the 1950’s, but their use was limited because of 
lower disease incidence and higher clinical heterogeneity compared to rats and guinea pigs (Gold et al., 
2006). Only after the introduction of pertussis toxin to enhance disease induction and the use of more 
susceptible mouse strains (Bernard and Carnegie, 1975; Levine and Sowinski, 1973), murine EAE models 
became of wider use. The development of genetic manipulation techniques to generate transgenic and 
knock-in/out mice, allowing studying the contribution of a plethora of genes in the disease development 
and progression, made mice the most predominant experimental animal for EAE studies (Handel et al., 
2011). 
In “classic” EAE phenotype, the clinical symptoms start with a loss of the tail tone. The paralysis 
progresses in caudal to rostral direction, first to hind legs and then upper limbs, accompanied by intense 
weight loss. The lesions are mainly located in the spinal cord and are dominated by CD4+ T cells and 
macrophages (Stromnes and Goverman, 2006a). The disease may spontaneously resolve (acute 
monophasic) or continue into a chronic paralysis (chronic). Alternatively, EAE can obtain a fluctuating 
course, with disease episodes followed by partial recovery (relapsing-remitting) (Wekerle, 2008). In 
contrast, untypical EAE phenotype is characterized by ataxia, spasticity, inability to walk straight and 
rolling in an axial-rotary manner (Stromnes and Goverman, 2006a).  The disease symptoms, severity and 
course depend on the mouse model. 
EAE is the best available animal model to study MS, as individual variants of EAE reflect different aspects 
of the human disease (Krishnamoorthy and Wekerle, 2009). However, despite the obvious relevance of 
EAE to MS, there are several key differences between the human disease and its animal model. Firstly, 
while MS is a spontaneously occurring disease and the antigen(s) is not yet known, in EAE the 
experimental mice are immunized with specific myelin proteins or peptides. Even in recently developed 
spontaneous EAE models, the T cells bear myelin antigen-specific T cell receptor (TCR). Secondly, in most 
of EAE protocols, strong immune adjuvants are used to induce the disease, while under physiological 
conditions such intense immune system activation is unlikely to occur (Gold et al., 2006). Moreover, for 
practical reasons and for experimental reproducibility, the animals used in EAE studies are highly inbred, 
genetically homogeneous and housed in pathogen-free, controlled environment, thus not reflecting the 
genetic heterogeneity of human populations and the environmental factors that contribute to the MS 
susceptibility (Handel et al., 2011). In addition, while EAE is a CD4+ T cell-mediated disease, MS lesions 
are dominated by CD8+ T cells and macrophages, with CD4+ T cells being infrequent (Sriram and Steiner, 
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2005). Lastly, some therapeutic approaches that have been successful in EAE, such as tumor necrosis 
factor (TNF) blocking, have failed dramatically in MS clinical trials (Probert and Akassoglou, 2001; 
Wekerle, 2008). In total, EAE is a useful tool for studying the basic mechanisms of MS such as BBB 
disruption, lymphocyte trafficking, CNS inflammation and demyelination, as well as for validating 
possible therapeutic compounds. Indeed, the knowledge obtained by studying different EAE models has 
fundamentally shaped our understanding of not only MS mechanism, but also aspects of self-tolerance 
and autoimmune responses in general. However, the differences with MS should be always considered 
when attempting to extrapolate the results from EAE studies to the human disease. 
1.2.1 Induced EAE Murine Models 
The most common way of EAE induction is by active immunization (actively induced EAE – aEAE), with 
subcutaneous injection of myelin proteins or peptides, emulsified in complete Freund’s adjuvant (CFA). 
CFA consists of heat-inactivated Mycobacterium tuberculosis, which enhances the innate immune 
response, in mineral oil, allowing gradual but constant release of the antigen. Additionally, pertussis 
toxin is injected intraperitoneally on day 0 and day 2 post immunization, which is considered to facilitate 
the BBB opening and subsequent immune cell infiltration into the CNS (Stromnes and Goverman, 2006a). 
The type of the disease course (acute, chronic, relapsing-remitting) and pathology depend on the mouse 
strain and the antigen used for immunization (see Table 1.1). Myelin basic protein (MBP), myelin 
oligondendrocyte glycoprotein (MOG) and proteolipid protein (PLP), which are all myelin components, 
and peptides derived from them are the most frequently used antigens. Active immunization of C57BL/6 
mice with MOG35-55 is the main model in the present study.  
Mouse strain MHC Peptide Peptide sequence Clinical course 
B10.PL H-2u MBP Ac1-9 Ac-ASQKRPSQR Relapsing-remitting 
C57BL/6 H-2b MOG35-55 MEVGWYRSPFSRVVHLYRNGK Monophasic 
SJL/J H-2s PLP139-151 HCLGKWLGHPDKF Relapsing-remitting 
  
PLP178-191 NTWTTCQSIAFPSK Relapsing-remitting 
  
MBP84-104 VHFFKNIVTPRTPPPSQGKGR Relapsing-remitting 
  
MOG92-106 DEGGYTCFFRDHSYQ Relapsing-remitting 
Table 1.1 Commonly used actively induced murine EAE models [adapted from (Krishnamoorthy and Wekerle, 2009; 
Stromnes and Goverman, 2006a)] 
Alternatively, EAE can be induced in recipient naïve animals by adoptive transfer of encephalitogenic 
CD4+ T cells, isolated from actively immunized donor mice and stimulated ex vivo (passively transferred 
EAE – pEAE). This EAE induction technique has the advantage that, firstly, the autoaggressive T cells can 
be labeled prior to the adoptive transfer, in order to distinguish them from the host cells and to monitor 
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their location and activity. Moreover, pEAE offers the possibility of ex vivo manipulation (e.g. 
polarization) of the cells to be transferred, allowing the investigation of the pathogenicity of different T 
cell phenotypes (Stromnes and Goverman, 2006b). Finally, pEAE develops faster and permits the study of 
the effector phase independently from the initiation phase of the disease.  
1.2.2 Spontaneous EAE Murine Models 
The CFA inoculation and the bulk transfer of ex vivo stimulated T cells are important drawbacks of the 
induced EAE models, as disease triggering factors cannot be examined. The generation of myelin-specific 
TCR transgenic mice led to the development of spontaneous EAE mouse models, which circumvent the 
artificial disease initiation of the induced models. The first mice with T cells expressing transgenic TCR 
that recognize myelin antigens were MBP-specific TCR transgenic mice, which develop spontaneous EAE 
only when housed in non-sterile facility (Goverman et al., 1993) or crossed to immunodeficient 
background (Lafaille et al., 1994). In contrast, TCR transgenic mice for the PLP139–151/I-A
s epitope in SJL 
background develop spontaneous CNS autoimmunity in high incidence in specific pathogen free (SPF) 
conditions, without the need of RAG deficiency (Waldner et al., 2000). 
Our group has described two distinct spontaneous EAE models: First, the “opticospinal EAE” (OSE) 
mouse, a double transgenic mouse in C57BL/6 background which occurs by crossing the 2D2 (TCRMOG) 
mouse, where T cells bear TCR specific for MOG35-55 (Bettelli et al., 2003), with the Th (IgH
MOG) mouse, 
where B cells express B cell receptor (BCR) that carries a rearranged heavy chain of a MOG-specific 
antibody (Litzenburger et al., 1998). In the OSE model, MOG-specific T cells and B cells cooperate to 
induce spontaneous chronic opticospinal EAE at the age of four to eight weeks, with 50% incidence 
(Bettelli et al., 2006a; Krishnamoorthy et al., 2006). The second spontaneous EAE model is the “relapsing-
remitting” (RR) mouse, a single transgenic mouse in SJL/J background, where T cells carry TCR that 
recognizes MOG92-106. Interestingly, in this model the transgenic T cells recruit MOG-specific B cells from 
the endogenous repertoire, leading to relapsing-remitting EAE at the age of two months, with 80% 
incidence (Pollinger et al., 2009). These spontaneous EAE models, where T and B cell cooperation is 
inducing the disease without experimental manipulation, resemble closely two distinct types of MS 
(opticospinal and RR MS), providing a powerful tool to elucidate the factors determining the outbreak 
and course of the human disease. 
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1.3 Immune Cell Infiltration into the CNS 
1.3.1 Disease Mechanism 
In EAE, autoaggressive CD4+ T cells are primed in the periphery by professional antigen presenting cells 
(APC) of the dendritic cell lineage (Gold et al., 2006). Once activated, the CD4+ T cells are able to cross 
the BBB, which consists of highly specialized endothelial cells of low pinocytotic activity and firmly 
connected with tight junctions, supported by an underlying endothelial basement membrane, that 
contains pericytes, and the glia limitans (Engelhardt and Coisne, 2011). First, T cells are captured and 
firmly adhered to the endothelial cells by α4-integrin/VCAM-1 interactions. Their subsequent crawling on 
the endothelium preferentially against the blood flow, until they find a site for diapedesis, is mediated by 
αLβ2 (LFA-1)/ICAM-1 interaction (Engelhardt and Coisne, 2011). T cells extravasate only at the level of 
post-capillary venules (Engelhardt and Ransohoff, 2005) to reach the perivascular space, where they get 
re-activated by encountering APC, that can be either infiltrating dendritic cells (DC) and perivascular 
macrophages or local microglia and astrocytes (Dittel, 2008). Despite the low numbers of DC in the CNS, 
vessel-associated CD11c+ DC have been shown to be sufficient to induce EAE (Greter et al., 2005), while 
peripheral derived CNS myeloid CD11b+ DC can polarize effector T cells to Th17 cells (Bailey et al., 2007). 
During EAE, perivascular macrophages upregulate MHC II and costimulatory molecule expression, 
turning into potent APC (Fabriek et al., 2005). Similarly, while microglial cells have poor antigen 
presenting capacity in resting state, they upregulate most immunophenotypical markers during CNS 
inflammation (Galea et al., 2007). The activated microglia resembles macrophages both phenotypically 
and morphologically, thus it is difficult to be differentiated from the infiltrating macrophages during EAE 
(Dittel, 2008). In contrast, MHC II+ astrocytes are detected rarely and only under strong inflammatory 
conditions, but they influence the inflammatory response by producing cytokines and chemokines 
(Aloisi, 2001; Goverman, 2009). In total, the T cell reactivation in the perivascular space not only 
determines the amount of subsequent parenchymal inflammation, but also results in the secretion of a 
variety of cytokines and chemokines, that play a crucial role in the local milieu modification and the 
outcome of the immune response (Gold et al., 2006; Goverman, 2009). 
The re-activated CD4+ T cells secrete proinflammatory cytokines, including interferon γ (IFNγ), 
interleukin 17 (ΙL-17), granulocyte-macrophage colony-stimulating factor (GM-CSF), or tumor necrosis 
factor α (TNFα), that recruit further immune cells and activate macrophages and microglia. These cells 
mediate oligodendrocyte damage or direct neuronal toxicity, by producing TNFα and IL-1β, as well as 
effector molecules such as nitric oxide (NO) and reactive oxygen species (ROS) (Herz et al., 2010). 
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Autoantibodies against myelin proteins can also contribute to myelin sheath destruction. Eventually, the 
CNS inflammation leads to demyelination and axonal degeneration, resulting in the clinical symptoms. 
 
Figure 1.1 Immunopathogenesis of MS and EAE [adapted from (Domingues, 2009)] 
1.3.2 T and B lymphocytes in EAE 
T cell subsets in EAE 
Both in MS and EAE, T cells play the most important role in the disease development. Although 
susceptibility to MS is strongly associated with HLA class II genes, CD8+ T cells are more abundant than 
CD4+ T cell and show clonal expansion in human MS lesions, while CD8+ memory T cell are enriched in 
the CSF and blood of MS patients, compared to CD4+ memory T cells (Friese and Fugger, 2005; 
Goverman, 2009). However, only few reports have shown that CD8+ T cell can induce EAE (Huseby et al., 
2001; Sun et al., 2001). In contrast, in the vast majority of EAE models, the disease is mediated by CD4+ 
T cells, while CD8+ T cells are found in very low frequency in the CNS infiltrates and their role is poorly 
understood. 
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Distinct subsets of CD4+ T cells have been described, defined by their cytokine profile and expression of 
particular transcription factors. First, the T helper 1 and 2 (Th1 and Th2) paradigm was introduced 
(Mosmann et al., 1986). More recently, two newly characterized subsets, with key roles in 
autoimmunity, were added: Th17 cells (Park et al., 2005) and regulatory T cells (Treg) (Fontenot et al., 
2003; Hori et al., 2003). In the last few years, additional T cell subtypes were suggested based on their 
signature cytokines, such as Th9 (Veldhoen et al., 2008) and Th22 (Eyerich et al., 2009), although it is still 
not clear whether they represent stable cell lineages. Th1 and Th17 are now considered as the effector 
T cells involved in EAE pathology, while Treg are crucial for the maintenance of immunosuppression. The 
importance of Treg in EAE is the main topic of this thesis and will be addressed in detail in further 
sections. 
Th1 cells need IL-12 for their differentiation, express the transcription factor T-bet and are characterized 
by the secretion of mainly IFNγ, but also IL-2 and TNFα. They enhance pro-inflammatory cell-mediated 
immunity and induce delayed-type hypersensitivity (DTH) responses, as well as production of opsonizing 
isotypes of IgG by B cells (Qureshi et al., 2011).  Th1 cells were until some years ago the sole mediators in 
EAE, as CNS infiltrating T cells produce high levels of IFNγ and adoptive transfer of myelin-specific Th1 
cells to naïve animals induces disease (Goverman, 2009). In addition, T-bet deficient mice are resistant to 
EAE induction (Bettelli et al., 2004) and neutralizing IL-12 p40 subunit prevents the disease (Leonard et 
al., 1995). 
However, paradoxically to this concept, Ifng-/- (Ferber et al., 1996) and Ifngr-/- (Willenborg et al., 1996), as 
well as Il12 p35-/- (Becher et al., 2002) mice were found to develop more severe EAE.  In contrast, 
Il23 p19-/- mice, which are deficient for IL-23 but not IL-12, are completely resistant to EAE (Cua et al., 
2003). Since IL-12 and IL-23 share p40 subunit, the inhibition of p40 results in suppression of both 
interleukins. However, Il12 p35-/- or Il23 p19-/- mice lack IL-12 or IL-23, respectively. Therefore, these 
observations suggest the existence of unknown effector T cell subset. IL-23 promotes the secretion of IL-
17 in CD4+ T cells, together with transforming growth factor-β (TGF-β) and IL-6 (Veldhoen et al., 2006). 
Since they were not fitting to the Th1/Th2 paradigm, these IL-17-producing CD4+ T cells were termed 
Th17 cells, with RORγt as their key transcription factor (Ivanov et al., 2006). Th17 cells are present in the 
CNS infiltrates and adoptive transfer of Th17 cells induces strong disease, suggesting a pathogenic role 
for Th17 cells in EAE (Goverman, 2009; Petermann and Korn, 2011). IL-17 is also highly upregulated in MS 
lesions (Petermann and Korn, 2011; Zhou et al., 2009a). However, IL-17 deficient mice are still 
susceptible to EAE presumably due to the contribution of other factors secreted by Th17 cells. To 
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complicate things further, T-bet, a transcription factor associated with Th1 cells, is also necessary for the 
generation of pathogenic Th17 cells (Yang et al., 2009) 
B cells in EAE 
B cells play a prominent role in MS, as clearly suggested by the positive effects of B cell depletion using 
anti-CD20 antibody (Rituximab) (Liang et al., 2008) and the presence of oligoclonal bands in the CSF in 
MS patients. B cells can produce proinflammatory cytokines and chemokines, function as APC and 
secrete autoantibodies that mediate demyelination (Huang et al., 2004). However, despite the profound 
contribution of B cells in MS pathogenesis, their role in the majority of EAE models is debated. On the 
one hand, aEAE induction by immunization with myelin peptides is antibody-independent and on the 
other hand, transfer of encephalitogenic T cells in recipient animals is sufficient to induce pEAE without 
any antibody involvement. Intriguingly though, despite B cell-deficient mice develop EAE upon MOG35-55 
immunization, they are resistant to the disease when immunized with recombinant MOG (Yu et al., 
2009), while injection of MOG-primed serum restores their susceptibility (Solomon et al., 2011). 
Additionally, while the aforementioned MOG-specific BCR knock-in mice (Th) mice do not develop 
spontaneous EAE, despite their high titers of MOG-specific IgG antibodies, they show accelerated and 
exacerbated disease upon immunization (Litzenburger et al., 1998). In contrast, other studies have 
revealed that B cells are essential for mediating recovery from EAE by producing IL-10 (Lyons et al., 2008; 
Wolf et al., 1996; Zheng et al., 2009) and regulating Treg via B-7 (Chaudhry et al., 2009). Therefore, 
different subtypes of B cells appear to have distinct effects in induced EAE (Matsushita et al., 2008).  
Interestingly, B cells are pivotal in two spontaneous EAE models described in previous section, the OSE 
and RR mouse. Firstly, while MOG-specific TCR transgenic mice (2D2) develop spontaneous EAE in very 
low incidence (5%) (Bettelli et al., 2003), once crossed to Th mice, the double transgenic OSE mice 
display spontaneous EAE incidence around 50%, suggesting a cooperation between T cells and B cells 
that are specific for the same antigen (Bettelli et al., 2006a; Krishnamoorthy et al., 2006). Secondly, in 
the RR model, the MOG-specific T cells recruit MOG-specific B cells from the endogenous repertoire and 
guide them to produce pathogenic autoantibodies that contribute to the development of spontaneous 
relapsing-remitting EAE in high incidence, characterized by demyelination. Moreover, anti-CD20 
antibody-mediated ablation of B cells in neonatal RR mice suppressed the disease development 
(Pollinger et al., 2009). Therefore, B cells play fundamental role in these spontaneous EAE models. 
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1.4 Regulatory T cells 
CD4+ Forkhead box P3+ (Foxp3+) regulatory T cells (Treg) are critical for maintaining immune homeostasis 
and self-tolerance, as well as modulating immune responses in the contexts of infection, autoimmunity, 
cancer and transplantation (Campbell and Koch, 2011). Already in the 80’s, several studies reported that 
T cells have the capacity to prevent or suppress deleterious immune reactions (Hall, 1985; Kong et al., 
1989; Sakaguchi et al., 1982). Nevertheless, the existence of a suppressor T cell subtype was 
underestimated, because of poor characterization of these cells and lack of specific markers. This 
changed in 1995, when a population of IL-2 receptor α-chain (CD25)-expressing CD4+ T cells was 
described to preserve self-tolerance and regulate immune responses against self and non-self-antigens 
(Sakaguchi et al., 1995). In addition, CD4+CD25+ T cells were further shown to suppress T cell 
proliferation in vitro (Thornton and Shevach, 1998). However, as activated CD4+ T cells also upregulate 
CD25 expression, CD4+CD25+ regulatory T cells could not be identified as a distinct T cell subset. 
Therefore, the next major breakthrough in understanding Treg cell biology was the finding that patients 
with immune dysregulation, polyendocrinopathy, enteropathy X-linked (IPEX) syndrome, a rare fatal 
autoimmune disorder affecting a variety of organs, as well as mice with scurfy phenotype, carry 
mutations in the X chromosome-encoded Foxp3 gene (Bennett et al., 2001; Brunkow et al., 2001; Chatila 
et al., 2000). Soon after, Foxp3 was identified as the master transcription factor of Treg, essential for 
their differentiation and suppressor function, thus establishing Treg as a separate T cell lineage 
(Fontenot et al., 2003; Gavin et al., 2007; Hori et al., 2003; Khattri et al., 2003).  
The primary function of Treg has been originally defined as prevention of autoimmunity by maintaining 
immunologic self-tolerance (Sakaguchi et al., 1995). Indeed, Treg depletion in neonatal or adult mice was 
found to result in fatal multi-organ autoimmunity, underscoring the importance of this T cell subset for 
preserving peripheral tolerance throughout the lifespan of an individual (Kim et al., 2007; Lahl et al., 
2007). Furthermore, the ability of Treg to prevent or suppress autoimmune responses has been 
demonstrated in several experimental disease models, such as murine systemic lupus erythematosus 
(SLE) models (Scalapino et al., 2006; Wolf et al., 2005), collagen-induced arthritis (Morgan et al., 2003), 
autoimmune diabetes (Sgouroudis and Piccirillo, 2009) and colitis (Makita et al., 2007). In parallel, 
decreased numbers or impaired suppressive capacity of Treg have been reported in patients with 
systemic or organ-specific autoimmune diseases, including SLE (Kuhn et al., 2009), rheumatoid arthritis 
(Oh et al., 2010), type-1 diabetes (Zhang et al., 2012) and inflammatory bowel disease (Boden and 
Snapper, 2008). The studies on Treg role in MS and EAE will be discussed in detail in a separate chapter 
(see Treg in CNS Autoimmunity). Additionally, over the last years, further beneficial functions have been 
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attributed to Treg, such as modulating allergic responses (Braga et al., 2011), mediating tolerance against 
alloantigens after transplantation (Wood, 2011) and preventing fetal rejection during pregnancy (Leber 
et al., 2010). However, Treg function can be a double-edged sword during infections, as on the one hand 
they favor pathogen survival, but on the other hand they restrain immunopathologic reactions that can 
be deleterious to the host (Sanchez and Yang, 2011). Finally, Treg are considered key players in tumor 
immunity, as they infiltrate tumors and limit antitumor immune responses, promoting progression of 
cancer (Nishikawa and Sakaguchi, 2010). 
The instrumental role of Treg in the control of immune responses has placed this T cell subset in the 
center of scientific interest, as clinical implementation of their regulatory activity is challenging. Firstly, 
Treg number or activity could be modified in patients, depending on the clinical condition, by in vivo 
administration of specific agents. Alternatively, Treg could be isolated from patients, expanded ex vivo 
and reinfused, offering a personalized treatment (Riley et al., 2009). However, apart from technical and 
ethical issues, such approaches require in depth knowledge of Treg differentiation and stability, as well 
as in vivo suppression mechanisms. These issues will be discussed in the following sections.  
In conclusion, it is of vital importance to improve our understanding of Treg biology so that it can be 
potentially translated into therapeutic applications. 
1.4.1 Treg Differentiation 
Treg can be generated in vivo either in the thymus (natural Treg – nTreg) or differentiate from naïve CD4+ 
T cells in periphery (induced Treg – iTreg). A commonly used marker to distinguish nTreg and iTreg is the 
transcription factor Helios that is expressed only in nTreg (Thornton et al., 2010), although the reliability 
of this marker has been questioned recently (Verhagen and Wraith, 2010). The majority of the circulating 
Treg are of thymic origin (Geiger and Tauro, 2012; Josefowicz et al., 2012a). Nevertheless, nTreg and 
iTreg display distinct specificity, stability and genetic profile and serve different functions in immune 
homeostasis and responses (Geiger and Tauro, 2012). 
Treg Differentiation in the Thymus 
Foxp3 induction and Treg differentiation is instructed by TCR signaling in the thymus (Josefowicz et al., 
2012a). Sequence analysis studies that compared Treg and non-Treg cell TCR repertoires revealed that 
Treg express TCRα of broad variety that overlap only partially with non Treg TCRα sequences (Hsieh et 
al., 2004; Pacholczyk et al., 2006; Pacholczyk and Kern, 2008; Wong et al., 2007). Interestingly, transfer of 
Teff transfected with Treg TCR into lymphopenic mice resulted in rapid in vivo expansion of Teff and 
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induction of wasting disease, indicating increased self-reactivity of Treg TCRs. However, these Treg TCR-
expressing Teff mounted only weak responses in vitro against syngeneic APC, contrary to robust 
responses against the transgenic TCR-recognized foreign ligand, suggesting that the affinity range of non-
Treg TCR that recognize a foreign antigen is higher than the range of affinities of Treg TCR for self 
antigens (Hsieh et al., 2004). Moreover, reduced MHC II expression in medullary thymic epithelial cells 
(mTEC) led not only to partially impaired negative selection, but also increased frequency of Treg 
(Hinterberger et al., 2010). 
In addition, the increased negative selection in TGF-β receptor (TGF-βR) II-deficient mice resulted in 
reduced Treg number (Ouyang et al., 2010). Furthermore, in Foxp3-deficient mice, activated T cells 
preferentially used TCR that are normally expressed in Treg in Foxp3-sufficient mice, indicating that on 
the one hand these self-reactive TCR contribute to the pathology seen in these mice and on the other 
hand that these T cells can escape from negative selection despite not expressing Foxp3 (Hsieh et al., 
2006). Similarly, in mice expressing Foxp3 reporter null allele (Gavin et al., 2007) or a truncated Foxp3 
protein (Lin et al., 2007), CD4+ T cells expressing these nonfunctional alleles as well as self-reactive TCRs, 
are not deleted but become activated and induce autoimmune disease similar to Foxp3-deficient mice. 
In conclusion, Treg selection is instructed by TCR signals of intermediate strength, in the range between 
the weaker TCR affinities that mediate positive selection and the stronger signals that lead to negative 
selection of CD4+ single positive (SP) T cells in the thymus, while Foxp3 expression is not required for 
escaping from negative selection (Josefowicz et al., 2012a). Importantly, the broad Treg TCR repertoire 
has been shown to be a result of intense intraclonal precursor competition that restricts the 
differentiation of Treg cells expressing TCR of identical specificity (Bautista et al., 2009; Leung et al., 
2009).  
The fact that the same TCR can be expressed both by Treg and non-Treg cells suggests that TCR signaling 
alone is not sufficient to induce Foxp3 expression and Treg differentiation. Indeed, essential additional 
signals for Treg fate determination include mainly IL-2, as IL-2 or IL-2Rα-deficient mice have a significant 
decrease in Foxp3+ T cells in the thymus. In contrast, loss of IL-7 or IL-15, that act also through the 
common gamma-chain (γc) cytokine receptors, does not affect Treg generation. Nonetheless, combined 
ablation of IL-2, IL-7 and IL-5 or deficiency in γc cytokine receptor prevents completely Treg 
differentiation both in thymus and periphery (Burchill et al., 2007a; Fontenot et al., 2005; Josefowicz et 
al., 2012a). Therefore, as CD25+Foxp3- thymocytes were identified as precursors of Treg in the neonatal 
thymus, a two-step model of thymic Treg generation was suggested (Burchill et al., 2008; Lio and Hsieh, 
2008), according to which strong TCR signals lead to CD25 upregulation in Treg precursors, increasing 
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responsiveness to IL-2 signaling that subsequently mediates Foxp3 induction. Interestingly, STAT5, a 
transcription factor that is activated downstream of IL-2 and other γc cytokine receptors, has been 
shown to modulate Foxp3 expression, by binding to the Foxp3 promoter and the Foxp3-CNS2 element. 
Indeed, Stat5 ablation in DP thymocytes leads to strong reduction in Foxp3+ thymocytes, whereas 
expression of constitutively active STAT5 increases Treg numbers even in the absence of IL-2 (Burchill et 
al., 2003; Burchill et al., 2007b; Yao et al., 2007). In contrast, while TGF-βR signaling plays a pivotal role in 
peripheral Treg differentiation (see next section), within the thymus it does not induce Foxp3 expression 
but only promotes Treg precursor survival (Josefowicz et al., 2012a). 
 
Figure 1.2 TCR signal strength in thymus instructs CD4+ T cell fate and Treg differentiation [from (Josefowicz et al., 
2012a)] 
Besides TCR and cytokine stimulation, CD28 costimulatory signaling is critical for thymic Treg generation, 
as CD28-, as well as CD80-CD86-deficient mice display significant decrease in Treg frequencies, while the 
Ick-binding domain of the CD28 cytoplasmic tail is essential for Foxp3 induction (Salomon et al., 2000; Tai 
et al., 2005). Furthermore, TCR/CD28-downstream transcription factors, including NFAT, AP-1 and NF-κB, 
have been implicated in Treg differentiation. In fact, NFAT and AP-1 can bind to the Foxp3 promoter 
(Mantel et al., 2006), while targeted ablation or mutations of genes involved in the NF-κΒ signaling 
pathway, such as PKCθ, CARMA1, Bcl10, IκB kinase (IKK) 2 and p-105 encoding gene, result in impaired 
Treg generation. Additionally, several studies have underscored the crucial role of c-Rel, a NF-κΒ family 
member that can bind to the intronic conserved noncoding element Foxp3-CNS3, increasing the 
probability of Foxp3 induction in Treg precursor cells (Isomura et al., 2009; Ruan et al., 2009; Visekruna 
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et al., 2010; Zheng et al., 2010). Intriguingly, the role of cytotoxic T lymphocyte associated antigen-4 
(CTLA-4), a surface molecule exclusively and constitutively expressed by Treg, in Treg thymic 
development is heavily debated, with contradictory evidence from several studies (Verhagen et al., 2009; 
Verhagen et al., 2013; Zheng et al., 2006). Finally, further factors have been reported to promote Foxp3 
expression in thymocytes, including loss of maintenance DNA methyltransferase I (Dnnmt1) activity, 
deficiency in mTOR or sphingosine-1 phosphate receptor type 1 (S1P1), and reduction of PI3K signaling 
(Josefowicz et al., 2012a). 
Peripheral Treg Differentiation 
In contrast to nTreg cells that are generated in the highly controlled microenvironment of the thymus, 
promoted by high affinity interactions with self-peptide-MHC II complexes, iTreg differentiation takes 
place under various conditions and most likely in response to non-self-antigens (Josefowicz et al., 2012a). 
iTreg generation can occur in gut associated lymphoid tissue (GALT), spleen, inflamed and transplanted 
tissues, though many aspects of the in vivo processes remain to be elucidated. Nevertheless, in vitro and 
in vivo studies have established the basic requirements for Treg differentiation from naïve T cells, that 
include TCR stimulation along with the cytokines TGF-β and IL-2 (Curotto de Lafaille and Lafaille, 2009). 
Extrathymic differentiation of Treg cells has been demonstrated to depend on TCR ligand density and 
affinity, as low dose of strong TCR ligand leads to most efficient Foxp3 induction in vivo (Gottschalk et al., 
2010). Although iTreg differentiate from naïve CD4+ T cells, they use distinct TCRs compared to non-Treg 
CD4+ T cells. In fact, when Foxp3- CD4+ T cells are transferred in lymphopenic mice, the TCR repertoire of 
Foxp3+ T cells that occur has been shown to be different from the TCR repertoire of the remained Foxp3- 
cells, suggesting that TCR of certain specificities promote iTreg differentiation (Lathrop et al., 2008). 
Moreover, colonic iTreg display TCRs that are reactive to local antigens, derived mainly from commensal 
microbiota, and are different from TCRs from Treg in other locations (Lathrop et al., 2011). Therefore, 
iTreg differentiation is supported by TCRs specific for antigens to which an organism is chronically 
exposed under physiological conditions, such as commensal microflora. Importantly, the unique iTreg 
TCR repertoire implies that iTreg have different functions from nTreg, that can be determined by their 
antigen specificity.  
In addition to TCR stimulation, cytokine signaling plays a critical role in peripheral Treg generation. TGF-β 
has been consistently shown to be indispensable for in vitro and in vivo iTreg differentiation. Addition of 
TGF-β to cultures of naïve CD4+ T cells along with TCR stimulus, induced Foxp3 expression and led to 
acquisition of suppressive function both in vitro and in vivo (Chen et al., 2003). Moreover, blocking TGF-β 
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in vivo has been reported to impair the differentiation of antigen-specific Treg (Mucida et al., 2005) and 
inhibit the protection against colitis (Oida et al., 2003). TGF-β signaling can induce iTreg differentiation 
and development through different mechanisms, such as binding of Smad3 to Foxp3-CNS1 together with 
NFAT and opposition of Dnnmt1 recruitment (Josefowicz et al., 2012a). Furthermore, IL-2 is also essential 
for TGF-β-mediated induction of Foxp3 in CD4+ T cells in vitro (Davidson et al., 2007; Horwitz et al., 
2008). IL-2 not only acts through STAT5 to activate the Foxp3 locus while promoting cell survival, but also 
inhibits polarization to Th17 phenotype (Laurence et al., 2007). 
Further co-stimulation requirements have been described for iTreg generation. Interestingly, CTLA-4, 
independently of its role for Treg development in the thymus, has been shown to be essential for in vitro 
iTreg differentiation (Zheng et al., 2006). Moreover, retinoid acid (RA), that can be also produced by 
CD103+ DCs, has been demonstrated to promote iTreg differentiation and growth, while inducing a gut-
homing phenotype (Benson et al., 2007). In contrast, CD28 cross-linking has been reported to inhibit 
iTreg development (Kim and Rudensky, 2006).  
As extrathymic Treg differentiation has specific prerequisites, iTreg generation is limited to particular 
tissues and microenvironments (Josefowicz et al., 2012a). GALT serves as the main site of iTreg 
induction, as it provides constitutively antigens derived from commensal microbiota and food. In fact, 
germ-free mice have been shown to have reduced numbers of Treg in their colon, while colonization 
with specific bacteria led to a significant increase in the Treg number (Atarashi et al., 2011). Additionally, 
the gut and mesenteric LN harbor large numbers of CD103+ DCs, which mediate Treg conversion by 
producing TGF-β and RA (Coombes et al., 2007; Sun et al., 2007). The profound presence of iTreg in the 
GALT raises questions regarding their possible function in this niche. Interestingly, iTreg cells have been 
recently demonstrated to restrain allergic-type inflammation at mucosal interfaces rather than Th1/Th17 
autoimmune responses, as iTreg-deficient mice develop spontaneously Th2-type pathologies in lungs 
and gastrointestinal tract (Josefowicz et al., 2012b). Besides the GALT, Treg differentiation occurs also in 
the spleen and has been reported to be mediated by CD8+DEC205+ DCs that produce TGF-β (Yamazaki et 
al., 2008). 
Foxp3 expression and stability 
Foxp3 has an instrumental role for Treg identity and function. The contribution of Foxp3 in the 
transcriptional and functional characteristics of Treg was investigated in aforementioned studies using 
mice harboring a Foxp3 null allele (Gavin et al., 2007) or a truncated version of the Foxp3 protein lacking 
the DNA-binding domain (Lin et al., 2007), which showed that Foxp3 is indispensable for the suppressive 
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capacity, proliferative activity and metabolic fitness of Treg cells. Moreover, Foxp3 represses production 
of proinflammatory cytokines, such as IL-2, TNFα, IFNγ, IL-4 and IL-17, the latter one by interacting 
directly with RORγt, the key transcription factor of Th17 cells, and modulating its transcriptional activity 
(Zhou et al., 2008). Furthermore, as mentioned earlier, T cells bearing TCR normally expressed by Treg 
are inducing aggressive autoimmune syndrome in Foxp3-deficient mice (Hsieh et al., 2006). Additionally, 
ablation of a conditional Foxp3 allele in mature Treg led to production of Th1 cytokines and loss of 
suppressive capacity (Williams and Rudensky, 2007). In parallel, decreased Foxp3 expression in Treg 
resulted in acquisition of Th2 phenotype by these cells and caused severe immune disease (Wan and 
Flavell, 2007). In total, these findings clearly suggest that continuous Foxp3 expression is absolutely 
necessary not only for the maintenance of Treg suppressor function, but also for preventing conversion 
of Treg to effector T cell types. Thus, given that Treg-expressed TCR display increased affinity for self-
peptides, the latter function of Foxp3 is of critical importance for maintaining immune homeostasis and 
preventing potential autoimmune responses. 
The stability of Foxp3 expression and, therefore, of Treg phenotype has been actively debated, creating a 
complicated picture. Several in vitro studies have reported loss of Foxp3 expression in Treg following 
exposure to IL-6 (Xu et al., 2007; Yang et al., 2008), OX40 (So and Croft, 2007; Vu et al., 2007) or dectin-1 
activated DC (Osorio et al., 2008). Moreover, another report suggested that the instability of Foxp3 
expression in Treg in vivo results in the generation of an ex-Treg population that has memory phenotype 
and the potential to induce autoimmune response (Zhou et al., 2009b). However, following transfer of 
CD4+Foxp3+ T cells to lymphopenic mice, the majority of Treg was demonstrated to display stability in 
Foxp3 expression, while only a minor fraction of the CD25- subpopulation lost it (Komatsu et al., 2009). 
Importantly, by using noninvasive inducible labeling of Foxp3-expressing cells and tracking their fate in 
vivo, Treg were shown to exhibit notably stable expression of Foxp3 under physiologic, lymphopenic and 
inflammatory conditions (Rubtsov et al., 2010). 
The mechanisms underlying the stable Foxp3 expression in mature Treg are of great interest. CpG 
dinucleotide methylation at the Foxp3 locus, at the promoter and at Foxp3-CNS2, has been repeatedly 
demonstrated to regulate Foxp3 expression. Indeed, demethylation of CpG motifs at the Foxp3 locus has 
been correlated with stable Foxp3 expression in human and mouse nTreg, while these elements remain 
methylated in in vitro generated iTreg with unstable expression of Foxp3 (Baron et al., 2007; Floess et al., 
2007; Polansky et al., 2008). In parallel, runt-related transcription factor 1 (Runx1) and core-binding 
factor β (Cbfβ) have been reported to be essential for maintenance of high levels of Foxp3 expression 
(Bruno et al., 2009; Kitoh et al., 2009; Klunker et al., 2009). Importantly, CNS2 has been shown to bind 
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Foxp3/Runx1/Cbfβ, CREB/ATF, NF-κΒ and Ets-1 protein complexes in a CNS2 CpG DNA demethylation-
depended manner (Polansky et al., 2010; Zheng et al., 2010). Therefore, Foxp3 protein complexes bind to 
the demethylated CNS2 to maintain stable Foxp3 expression, forming an autoregulatory loop that 
defines Treg lineage stability (Josefowicz et al., 2012a). 
1.4.2 Treg Suppression Mechanisms 
Despite the rapidly accumulating knowledge on Treg development and regulation of the immune 
homeostasis and responses, our understanding on the actual suppression mechanisms used by Treg 
remains rather limited and is based mostly on in vitro studies. Treg are considered capable of 
suppressing CD4+ Teff, CD8+ T cells, B cells, NK cells, monocytes and DC in both cell-to-cell contact-
dependent and independent ways (Gasteiger et al., 2013; Lourenco and La Cava, 2011; Shevach, 2009; 
Sitrin et al., 2013). However, the major target cells of Treg are Teff and DC. 
Teff as Targets of Treg-mediated Suppression 
Treg-secreted cytokines, including IL-10, IL-35 and TGF-β, have been implicated in Treg-mediated 
suppression. IL-10 production by Treg has been shown to be required for limiting immune responses at 
environmental surfaces, such as colon and lungs, although not essential for the control of systemic 
autoimmunity (Rubtsov et al., 2008). Similarly, IL-35-deficient Treg have been demonstrated to display 
decreased suppressive capacity in vitro and are unable to restrain homeostatic proliferation and cure 
inflammatory bowel disease in vivo (Collison et al., 2007). Moreover, Treg-produced TGF-β1 has been 
reported to be indispensable for inhibiting Th1 differentiation and inflammatory bowel disease in a 
transfer model (Li et al., 2007). 
Cytolytic mechanisms reported to be used by Treg are granzyme A-, granzyme B- and perforin-mediated. 
Activated human Treg have been reported to express granzyme A upon CD3 and CD46 stimulation and 
can lyse CD4+ and CD8+ T cells (Grossman et al., 2004). However, murine Treg were found to highly 
upregulate granzyme B, not granzyme A, expression (Josefowicz et al., 2012a). In fact, Treg have been 
demonstrated to induce apoptosis of Teff or antigen-presenting B cells in vitro via granzyme B (Gondek 
et al., 2005; Zhao et al., 2006). Importantly, granzyme B+ Treg were shown to be critical in vivo, both for 
skin graft tolerance and for suppressing tumor clearance (Cao et al., 2007; Gondek et al., 2008). There is 
contradictory evidence on the role of perforin as a Treg suppression mechanism. Although in some of the 
aforementioned studies Treg have been observed to act in a perforin-independent manner (Gondek et 
al., 2008; Gondek et al., 2005), others have underscored the importance of perforin in Treg suppression 
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(Cao et al., 2007; Grossman et al., 2004; Zhao et al., 2006). Moreover, Treg have been reported to induce 
cell cycle arrest and apoptosis to Teff by galectin-1, a β-galactosidase binding protein that is 
preferentially expressed in Treg and is upregulated upon TCR activation (Garin et al., 2007). However, 
stable Treg-Teff interactions have not been detected in explanted lymph nodes (Tang et al., 2006). 
Treg-mediated suppression by metabolic disruption of target cells has been also proposed. As already 
mentioned, Treg, as well as activated Teff, express high levels of IL-2R α chain (CD25). The constitutive 
high expression of IL-2R by Treg has been suggested to deprive Teff of IL-2 and, therefore, inhibit their 
proliferation and induce apoptosis (Pandiyan et al., 2007). This mechanism of suppression has been 
recently shown to be used by Treg to suppress NK cells (Gasteiger et al., 2013; Sitrin et al., 2013). 
Furthermore, Treg have been reported to suppress Teff by directly transferring the inhibitory second 
messenger cyclic adenosine monophosphate (cAMP) into Teff via gap junctions (Bopp et al., 2007). 
Additionally, the ectoenzymes CD39 and CD73, which are highly expressed on Treg, have been 
repeatedly shown to contribute to suppression of activated Teff, that express the adenosine A2A 
receptor, by generating pericellular adenosine from extracellular nucleotides that inhibits Teff 
proliferation (Deaglio et al., 2007; Kobie et al., 2006). 
 
Figure 1.3 Main mechanisms by which Treg can directly suppress Teff [from (Shevach, 2009)] 
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Interestingly, expression of different Th lineage-specific transcription factors by Treg is required for 
suppressing the respective Teff subtypes. For example, Treg-specific ablation of STAT3, a key 
transcription factor Th17 differentiation, impaired Th17 suppression by Treg and resulted in fatal 
intestinal immunopathology (Chaudhry et al., 2009). Similarly, in Treg, the amount of interferon 
regulatory factor-4 (IRF4), a transcription factor critical for Th2 induction, is dependent on Foxp3 
expression, while ablation of a conditional Irf4 allele in Treg led to selective dysregulation of Th2 
responses (Zheng et al., 2009). Consistent with these findings, Treg upregulation of T-bet, the Th1-
specifying transcription factor, in response to IFNγ, promoted expression of the chemokine receptor 
CXCR3, which enabled Treg to migrate and accumulate at the sites of Th1 responses (Koch et al., 2009). 
Interestingly, T-bet deficient Treg, despite not showing strongly reduced suppressor capacity, fail to 
regulate Th1, but not Th2 or Th17 responses. Therefore, these observations suggest expression of Teff 
lineage-specific transcription factors in Treg  cells can tailor their function to suppress distinct Teff 
responses, by inducing either specialized suppression capacities or acquisition of selective migration 
properties (Josefowicz et al., 2012a). 
DC as Targets of Treg-mediated Suppresion 
Treg have been proposed to directly affect APC function through several mechanisms. Firstly, CTLA-4, a 
Treg-specific surface molecule, has been repeatedly shown to be crucial for Treg-mediated suppression 
(Friedline et al., 2009; Read et al., 2006; Read et al., 2000; Takahashi et al., 2000). In fact, CTLA-4 has 
been demonstrated to induce down-regulation of CD80 and CD86 on DC via trans-endocytosis (Qureshi 
et al., 2011; Wing et al., 2008), in agreement with the notable expansion of DC observed early upon Treg 
depletion (Kim et al., 2007). Additionally, Treg have been found to form aggregates on DC in vitro in a 
LFA-1-dependent manner and down-modulate CD80/CD86 expression on DC in a LFA-1- and CTLA-4-
dependent manner (Onishi et al., 2008). Interestingly, interactions between Treg and immature DC can 
be promoted in vitro by neuropilin-1 (Nrp1), which is expressed on Treg but not on naïve Teff (Sarris et 
al., 2008). Moreover, Treg have been suggested to inhibit DC maturation and costimulatory capacity by 
engagement of MHC molecule on immature DC to lymphocyte activation gene-3 (LAG-3) (Liang et al., 
2008), a CD4 homolog that binds MHC II molecules with high affinity, which is considered to be essential 
for Treg suppressive activity (Huang et al., 2004). Furthermore, Treg can also modulate DC function 
through the surface protein TIGIT, a novel Ig family member expressed at high levels on Treg and 
activated Teff, which induces IL-10 and TGF-β production by DC (Yu et al., 2009). Importantly, by imaging 
lymph nodes using two-photon microscopy, stable contacts between Treg and DC in lymph nodes have 
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been visualized ex vivo (Tang et al., 2006), while Treg have been observed to inhibit stable contacts 
between Teff and DC in vivo. 
 
Figure 1.4 Main mechanisms by which Treg can directly suppress APC [from (Shevach, 2009)] 
1.4.3 Treg in CNS Autoimmunity 
Treg in MS 
Soon after the establishment of Treg as a distinct T cell subset with protective or suppressive role in 
autoimmunity, the Treg homeostasis and function in MS patients was investigated in several studies, 
with often contradictory results. Several groups have independently observed that the frequency of 
CD4+CD25high Treg does not differ in peripheral blood of MS patients and healthy controls (Feger et al., 
2007; Haas et al., 2005; Putheti et al., 2004; Viglietta et al., 2004), although decreased CD4+CD25+FOXP3+ 
levels in blood from RR-MS patients has been also described (Venken et al., 2008b). Other studies have 
reported changes in specific Treg subpopulations in MS patients, such as decrease of CD39+ Treg in RR-
MS patients (Borsellino et al., 2007) or increase of CD25- Treg during relapse (Fransson et al., 2010).  
The functionality of Treg in MS patients has been also assessed. CD4+CD25high Treg isolated from blood of 
patients with RR-MS were shown to have compromised capacity to suppress CD4+CD25- T cells upon anti-
CD3 activation (Viglietta et al., 2004). These findings were confirmed by stimulating also with MOG and 
MBP (Haas et al., 2005; Kumar et al., 2006). Importantly, by using Teff from both MS patients and 
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healthy controls in these experiments, the defect in MS patients’ Treg function was verified to be 
intrinsic to Treg and not related to an increased activation status or resistance of Teff (Venken et al., 
2010). Yet again, another study disagrees with the concept of impaired Treg suppression in RR-MS 
patients, reporting normal Treg function when IL-7 receptor α-chain (CD127)-expressing cells are 
removed from the analysis, as this marker is present on activated T cells but not Treg (Michel et al., 
2008). Nevertheless, diminished FoxP3 expression in both mRNA and protein level has been described in 
RR-MS patients (Huan et al., 2005; Venken et al., 2008b), while patients with SP-MS show normal Treg 
suppressive function and FOXP3 expression (Venken et al., 2006). In summary, while there is 
accumulating evidence for an impaired Treg function in MS patients, it is not yet clear whether Treg 
dysfunction has a causal role in MS or whether it reflects a general defect of the immune system as a 
result of the autoimmune disorder (Zozulya and Wiendl, 2008). 
The mechanisms that underlie the observed Treg defect in MS patients remain unclear. A possible 
explanation could be an altered generation of Treg in the thymus of MS patients. In fact, the number of 
recent thymic emigrant Treg (RTE-Treg, defined by the expression of CD31 and CD45RA) was observed to 
be reduced in the blood of both early and chronic MS patients, due to lower thymic development and 
migration of Treg to peripheral circulation (Haas et al., 2007; Venken et al., 2008a). Moreover, the 
decreased RTE-Treg frequency is accompanied with compensatory expansion of memory Treg, resulting 
in an unaffected total Treg number. Importantly, the MS-derived RTE-Treg display diminished 
suppressive properties and contracted T cell receptor Vβ repertoire, consistent with impaired clonal 
expansion of Treg that was described before (Viglietta et al., 2004). Interestingly, long-term treatment of 
RR-MS patients with glatiramer acetate (GA) was reported to expand the RTE-Treg and restore their 
suppressive function (Haas et al., 2009). A more recent study suggests that decreased IL-7 receptor α-
chain expression contributes to impaired Treg neogenesis in MS (Haas et al., 2011). 
The question whether Treg migrate to the CNS during MS is also important to address. Treg are enriched 
in the CSF of RR-MS but not SP-MS patients, as compared with peripheral blood (Feger et al., 2007; 
Fritzsching et al., 2011; Venken et al., 2008b). However, Treg are detected in only 70% of brain biopsies 
from MS patients and their number is rather low (Fritzsching et al., 2011), while they are not detectable 
by immunostaining of postmortem MS brain lesions (Tzartos et al., 2008). Therefore, the presence of 
Treg within the CNS during MS, as well as their possible role there, remains to be elucidated. 
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Treg in EAE 
Treg were implicated in EAE before the discovery of Foxp3 as their master transcription factor, defined 
by their expression of CD25 in CD4+ T cells. Early reports in the development of spontaneous EAE in MBP-
specific TCR transgenic mice when they are crossed to RAG-1-deficient background (T/R- mice) was 
attributed to the lack of CD4+TCRαβ T cells with suppressing capacities in these mice (Olivares-Villagomez 
et al., 1998). Indeed, transfer of CD4+CD25+ T cells from wild-type or RAG-1-competent (T/R-) mice 
prevented the spontaneous EAE development (Hori et al., 2002). Thus, Treg are protective in this model 
of spontaneous CNS autoimmunity. 
Furthermore, several studies have reported a suppressive role for Treg in induced EAE. Adoptive transfer 
experiments have shown that large quantities of CD4+CD25+ T cells injected before aEAE induction can 
reduce the disease severity in MOG35-55-immunized C57BL/6 mice (Kohm et al., 2002), as well as in PLP139-
151-immunized SJL mice (Zhang et al., 2004). In addition, transfer of CD4
+CD25+ Treg ameliorates also 
pEAE in C57BL/6 mice (Kohm et al., 2002). Interestingly, low numbers of CNS-derived CD4+CD25+ T cells 
are sufficient to ameliorate aEAE, while they show higher suppressive capacity in vitro compared to 
CD4+CD25+ T cells isolated from LN of naïve or EAE mice (McGeachy et al., 2005). Similarly, PLP-specific 
(5B6) CD4+CD25+ T cells were able to suppress PLP-induced EAE in SJL mice, as well as pEAE in RAG-
deficient SJL mice (Yu et al., 2005), while naïve (CD62Lhigh) MPB-specific (Tg4) CD4+CD25+ T cells protect 
MBP-immunized B10.PL mice against aEAE (Stephens et al., 2009). In both studies, low numbers of 
myelin-reactive Treg were transferred prior to EAE induction. Therefore, antigen-specific Treg may have 
higher potency of downregulating the CNS autoimmune response. Importantly, therapeutic approaches 
have shown that transfer of myelin-specific Treg at the peak of the disease or during the first EAE 
remission enhances recovery or reduces the severity of the disease during relapse, respectively 
(Fransson et al., 2012; Mekala and Geiger, 2005; Stephens et al., 2009), providing evidence that Treg cell 
therapy can be effective in CNS autoimmunity. 
In parallel, CD25+ T cell ablation experiments were performed to further assess the Treg role in EAE. 
Treatment with anti-CD25 antibody either prior to immunization (McGeachy et al., 2005; Montero et al., 
2004) or following immunization (but before EAE onset) (Gartner et al., 2006) led to disease 
exacerbation. Similar results were observed when anti-CD25 antibody treatment was performed during 
recovery phase in PLP139-151-immunized SJL mice (Zhang et al., 2004). Moreover, post-recovery, anti-CD25 
treatment was shown to restore susceptibility to EAE reinduction (McGeachy et al., 2005). In contrast, 
another study reported no influence in EAE disease progression in anti-CD25 antibody treated PLP139-151-
immunized SJL mice, using a different antibody clone, though (Kohm et al., 2004). Nevertheless, these 
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results should be interpreted with caution, as anti-CD25 antibody treatment does not lead to specific 
Treg depletion, but also affects the activated Teff population that also expresses CD25. 
Whether Treg exert their suppressive function at the peripheral lymphoid organs or within the inflamed 
CNS remains controversial. Interestingly, Treg are able to migrate to and accumulate in the CNS of mice 
with EAE and Treg frequency in the CNS has consistently been shown to correlate with recovery from the 
disease (Korn et al., 2007; McGeachy et al., 2005; O'Connor et al., 2007). Moreover, the latter two 
studies revealed that the increased Treg numbers in the CNS during the recovery phase is a result of local 
proliferation. In fact, MOG-specific Treg are expanded after MOG-immunization, as shown by using 
MOG35-55/IA
b tetramers (Korn et al., 2007). In total, these results indicate that Treg could mediate 
immune suppression within the CNS during EAE. However, despite the fact that CNS-isolated Treg can 
suppress in vitro MOG-specific (2D2) naïve T cells or T cells isolated from spleen of EAE mice, they fail to 
inhibit in vitro the proliferation of CNS-derived encephalitogenic Teff, suggesting that Treg are unable to 
control the autoimmune response within the target organ (Korn et al., 2007). 
Despite Treg have been observed to suppress different models of EAE in several studies, our 
understanding on how this suppression is accomplished remains poor. Although in vitro Treg-mediated 
suppression has been reported to be IL-10 independent (McGeachy et al., 2005), CD4+CD25+ T cells from 
IL-10-deficient mice were unable to suppress active EAE, suggesting that IL-10 is crucial for the Treg 
function in vivo (Zhang et al., 2004). Similarly, TGF-β has also been shown to be involved in the recovery 
from EAE, as Treg expressing TGF-β latency-associated peptide (LAP) display increased frequency during 
the recovery phase and in vivo blocking of TGF-β prevented recovery (Zhang et al., 2006). In addition, 
glucocorticoid-induced TNFR (GITR), expressed on resting Treg, is related with their function, as EAE 
exacerbation has been observed upon treatment with anti-GITR antibody (Kohm et al., 2004). Recently, 
Nrp1 expression in Treg has been demonstrated to attenuate EAE progression. Nrp1 deficiency in CD4+ 
T cells has been shown to increase EAE severity, along with higher Th17 frequency and impaired Treg 
function (Solomon et al., 2011). Intriguingly, against aforementioned studies, CTLA-4 has been suggested 
to be dispensable for Treg suppressive capacity in vivo in an EAE setting, as CTLA-4-deficient mice with 
MBP-specific TCR transgenic T cells do not develop spontaneous lymphoproliferative disease (as the 
CTLA-4 KO mice do) nor EAE, but show resistance to disease induction, along with higher frequency of 
Treg in spleen and thymus (Verhagen et al., 2009). In contrast, reduced Treg frequency both in periphery 
and the CNS of LFA-1-deficient mice, due to impairment in Treg generation, results in enhanced EAE 
severity upon MOG35-55-immunization (Gultner et al., 2010). Finally, Treg have been reported to prevent 
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Teff trafficking in the target organ, possibly by modulating the expression of CXCR4, syndecan and S1P1 
in immunized mice (Davidson and Shevach, 2011). 
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OBJECTIVES 
Treg have been identified as key players in prevention and suppression of autoimmunity in various 
diseases and experimental models. In EAE, the animal model for MS, the role of Treg remains unclear. On 
the one hand, Treg accumulation in the CNS of mice with EAE has been shown to parallel recovery from 
the disease. Moreover, elimination of Treg population by anti-CD25 Ab treatment has been observed to 
exacerbate EAE, while transfer of Treg to mice with EAE has been proven beneficial. On the other hand, 
CNS-infiltrating Treg have been reported to be unable to control the ongoing inflammation in the target 
tissue. Nonetheless, little is known about the site of Treg-mediated suppression, as well as the 
mechanisms Treg use to restrict the autoimmune response during EAE. 
Therefore, the primary aim of the present study is to examine the function of Treg in MOG-induced 
aEAE, firstly by investigating the effect of selective and effective depletion of the Treg population, not 
only on the course of EAE, but also on immune cells that are possible targets of Treg-mediated 
suppression. Secondly, intravital two-photon microscopy is used to visualize and analyze the locomotion 
of Treg within the inflamed CNS, as well as their possible interactions with other key immune cells, such 
as Teff and APC, during different phases of EAE. In addition, this cutting-edge technique allows the 
assessment of the motility pattern of Teff and their interactions with APC, with or without the presence 
of Treg. In total, this study aims to elucidate the mechanisms that Treg avail of to mediate recovery from 
EAE, as well as to identify the site of Treg-mediated suppression of the autoimmune response. Lastly, an 
important aim of this study is to decipher the role of Treg in a spontaneous EAE model, the OSE mouse. 
As only half of the OSE mice develop spontaneous EAE (sEAE), the possible contribution of Treg in 
resistance to the disease is investigated, on the one hand, by comparing the Treg frequency, antigen-
specificity and suppressive capacity between sEAE-affected and resistant mice, and on the other hand, 
by studying the effect of chronic Treg depletion in incidence and severity of sEAE. 
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MATERIAL & METHODS 
2.1 Material 
2.1.1 Mice 
All animals used in this study were bred in the animal facilities of the Max Planck Institutes of 
Biochemistry and Neurobiology. The animal procedures were in accordance with guidelines of the 
committee on animals of the Max Planck Institute for Neurobiology, and with the license of the 
Regierung von Oberbayern. 
Transgenic Mouse Lines (all C57BL/6 background) 
 Foxp3-GFP.KI (Bettelli et al., 2006b) 
Treg-GFP reporter mouse: GFP expression under the Foxp3 promoter. 
 DEREG (Lahl et al., 2007) 
“Depletion of Regulatory T cell” mouse: Bacterial artificial chromosome-transgenic mouse expressing 
a diphtheria toxin receptor-GFP fusion protein under the control of the foxp3 gene locus. 
 T-Red (Mempel et al., 2006) 
T cell-RFP reporter mouse: expression of dsRedII under the control of the murine CD4 promoter and 
proximal enhancer. 
 2D2 (Bettelli et al., 2003) 
MOG-specific TCR transgenic mouse: CD4+ T cells express a transgenic TCR recognizing MOG35-55 
peptide in the context of I-Ab. 
 Th (Litzenburger et al., 1998) 
MOG-specific BCR knock-in mouse: B cells express a rearranged Ig heavy chain of a MOG-specific 
antibody. 
2.1.2 Buffers and Reagents 
Phosphate buffered saline (PBS)  
10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4, 140 mM NaCl, 2.7 mM KCl 
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Erythrocyte lysis buffer 
0.83 % NH4Cl 
ACK buffer  
150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA 
Percoll (GE Healthcare) 
 Stock Isotonic Percoll (SIP): 9 parts (v/v) Percoll + 1 part (v/v) of NaCl 1.5 M (d=1.123) 
 Percoll d=1.080: 10 ml SIP + 5.7 ml PBS
Cell culture medium 
RPMI 1640 medium (Sigma-Aldrich) was complemented with 100 µM MEM non-essential amino acids, 1 
mM sodium pyruvate, 50,000 units penicillin, 50 mg streptomycin, 2 mM L-glutamine (all Gibco), and 
10 % heat inactivated fetal calf serum (FCS) (Biochrome), 200 µM β-Mercaptoethanol. Prior to use, FCS 
was inactivated for 1 hour at 56 C. Medium was sterilized by filtration (pore size 0.2 µm). Quantities 
refer to 500 ml of medium. 
Flow Cytometry buffers 
 FACS staining buffer: 1 % BSA, 0.1 % sodium azide in PBS 
 Foxp3 Fixation/Permeabilization Concentrate and Diluent (eBioscience) 
 Permeabilization Buffer (10X) (eBioscience) 
Fluorescence Immunohistochemistry buffers 
 Blocking buffer: 4 % BSA, 4 % goat serum in PBS 
 Staining buffer: 4 % BSA, 1 % goat serum, 0.1 % Triton 100x in PBS 
 Wash buffer: 1 % goat serum, 0.3 % Triton 100x in PBS 
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Antibodies for Flow Cytometry 
Flow cytometry antibodies were labeled with eFluor® 450, FITC, PE, PerCP-Cy5.5, PE-Cy7, APC, APC-
eFluor 780 or Alexa Fluor 647, or were biotinylated and used in conjunction with streptavidin-coupled 
fluorophores. 
Specificity Clone Antibody class Provider 
CD4 RM4-5 Rat IgG2a, κ eBioscience 
CD11b M1/70 Rat IgG2b, κ BD 
CD19 1D3 Rat IgG2a, κ BD 
CD25 PC61.5 Rat IgG1, κ eBioscience 
CD44 IM7 Rat IgG2b, κ BD 
CD45 30-F11 Rat IgG2b, κ eBioscience 
CD45R (B220) RA3-6B2 Rat IgG2a, κ eBioscience 
CD86 GL1 Rat IgG2a, κ eBioscience 
CD152 UC10-4B9 Armenian Hamster IgG eBioscience 
CD206 C068C2 Rat IgG2a, κ BioLegend 
Foxp3 FJK-16s Rat IgG2a, κ eBioscience 
I-A NIMR-4 Rat IgG2b eBioscience 
IFNγ XMG1.2 Rat IgG1, κ eBioscience 
IgMa DS-1 Mouse IgG1, κ BD 
IL-17A eBio17B7 Rat IgG2a, κ eBioscience 
Ki-67 B56 Mouse IgG1, κ BD 
TNFα MP6-XT22 Rat IgG1 BD 
Vα3.2 TCR RR3-16 Rat IgG2b, κ BD 
Vβ11 TCR RR3-15 Rat IgG2b, κ BD 
Streptavidin - - eBioscience 
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Primers for Real-Time quantitative PCR 
Gene Primer name Oligo sequence (5'→ 3') References 
GAPDH 
Sense TCACCACCATGGAGAAGGC 
Designed by Primer 
3 software 
Anti-sense GCTAAGCAGTTGGTGGTGCA 
Probe ATGCCCCCATGTTTGTGATGGGTGT 
IFNγ 
Sense TCAAGTGGCATAGATGTGGAAGAA 
(Giulietti et al., 
2001) 
Anti-sense TGGCTCTGCAGGATTTTCATG 
Probe TCACCATCCTTTTGCCAGTTCCTCCAG 
IL-17A 
Sense AACTCCCTTGGCGCAAAAGT 
Designed by Primer 
3 software 
Anti-sense GGCACTGAGCTTCCCAGATC 
Probe CCACGTCACCCTGGACTCTCCACC 
Antibodies for Fluorescent Immunohistochemistry 
Fluorescent Immunohistochemistry antibodies were labeled with FITC, Alexa Fluor 568, Alexa Fluor 647, 
or were biotinylated and used in conjunction with streptavidin-coupled fluorophores. 
Specificity Clone Antibody class Provider 
CD4 RM4-5 Rat IgG2a, κ BD 
CD4 RM4-5 Rat IgG2a, κ BioLegend 
CD11b M1/70 Rat IgG2a, κ BD 
Foxp3 FJK-16s Rat IgG2a, κ eBioscience 
Rat IgG (H+L) - Goat Ig Life Technologies 
Streptavidin - - Life Technologies 
Fluorescent Dextran Conjugates for Intravital 2-p Imaging 
Fluorophore MW Provider 
Alexa Fluor 488 10 kDa Life Technologies 
Alexa Fluor 647 10 kDa Life Technologies 
Alexa Fluor 680 10 kDa Life Technologies 
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2.2 Methods 
2.2.1 Mouse Routine 
Genotyping 
Peripheral blood mononuclear cell (PBMC) were isolated from transgenic mice and analyzed by FACS for 
fluorescent protein expression (GFP for Foxp3-GFP.KI and DEREG, dsRedII for T-Red), or transgenic TCR 
(2D2) or BCR (Th) by antibody staining specific for transgene.  
Leukocyte Isolation from Peripheral Blood 
4 to 6 droplets of blood were collected from anesthetized mice by retro-orbital bleeding into 100 µl of 
200 U/ml heparin (Sigma-Aldrich) in PBS. Erythrocytes were lysed by incubation in 1 ml ACK buffer 
(5 min, RT) and leukocytes were spun down (500 rcf, 5 min, 4 °C). After repeating once more the ACK 
incubation and spin down, leukocytes were finally resuspended in 150 µl FACS buffer. 
EAE induction 
EAE was induced by injecting the mice subcutaneously into the flanks with 200 μl of emulsion containing 
200 μg MOG35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) and 500 μg M. tuberculosis H37 Ra (Difco) in 
incomplete Freund Adjuvant oil (Difco). In addition, the mice received 400 ng pertussis toxin (List 
Biological Laboratories) intraperitoneally (i.p.) on days 0 and 2 after immunization. 
Clinical signs of EAE were assessed daily according to the following score: score 0 – no disease; score 0.5 
– reduced tail tonus; score 1 – limp tail; score 1.5 – limp tail and ataxia; score 2 – limp tail, ataxia and 
hind limb weakness; score 2.5 – at least one hind limb paralyzed/weakness; score 3 – both hind limbs 
paralyzed/weakness; score 3.5 – complete paralysis of hind limbs; score 4 – paralysis until hip; score 5 – 
moribund or dead.  
Diphtheria Toxin (DTx) Treatment 
For depletion of Treg in DEREG mice, DTx (Sigma-Aldrich) (200 ng in 100 µl PBS) was injected both i.p. 
and intravascularly (i.v.). For chronic depletion of Treg in OSE x DEREG mice, 100ng DTx (in 100 µl PBS) 
was injected i.p. twice per week for 5 weeks. 
Mononuclear Leukocyte Isolation from Organs 
Mice were anesthetized and perfused transcardially through left ventricle with 20 ml cold PBS. Lymphoid 
organs (spleen, inguinal and axillary lymph nodes), brain and spinal cord were dissected. 
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 Lymphoid organs 
Single cell suspension was prepared in RPMI by using 40 µm cell strainers (BD). Cells were 
centrifuged (500 rcf, 10 min, 4 °C) and the cell pellet was resuspended in complemented RPMI for 
further analysis. 
For spleen preparation, erythrocyte lysis was performed by resuspending and incubating the cells in 
0.83 % NH4Cl for 3 min at RT. Cells were washed with RPMI, centrifuged (500 rcf, 10 min, 4 °C) and 
resuspended in complemented RPMI.  
 CNS 
Single cell suspension was prepared in RPMI by using 100 µm cell strainers (BD). After centrifugation 
(500 rcf, 10 min, 4 °C), the cell pellet was resuspended in 5 ml RPMI plus 2.16 ml Stock Isotonic 
Percoll (SIP) and was overlaid on 5 ml Percoll d=1.080. The gradient was centrifuged (1200 rcf, 
20 min, RT) and the interface, containing the mononuclear cells, was collected, washed with 
complemented RPMI and resuspended in complemented RPMI for further analysis. 
2.2.2 Flow Cytometry (FACS) 
Surface Staining 
Cells were transferred in 96-well V bottom plate (Nunc), spun down (250 rcf, 10 min, 4 °C) and washed in 
200 µl FACS buffer. They were resuspended in 50 μl of a mix of labeled antibodies in FACS buffer at 
optimized dilutions and incubated in dark (20 min, 4 °C). After incubation, cells were washed twice in 200 
µl FACS buffer. When biotin antibodies were used, a secondary staining using fluorescently conjugated 
Streptavidin followed, using the same protocol. 
Intracellular Staining 
For intracellular cytokine staining (IFNγ, IL-17, TNFα), cells were activated with 50 ng/ml PMA (Sigma) 
and 500 ng/ml ionomycin (Sigma) in the presence of 5 µg/ml brefeldin A (Sigma) for 4 h at 37 °C. For 
Foxp3 and Ki-67 staining no PMA/ionomycin stimulation was performed. Upon completion of the surface 
staining, cells were fixed and permeabilized by incubation with Foxp3 Fixation/Permeabilization Buffer 
(eBioscience) in dark (30-60 min, RT). After washing twice in Permeabilization Buffer (eBioscience), cells 
were resuspended in 50 μl of a mix of labeled antibodies in Permeabilization Buffer at optimized 
dilutions and incubated in dark (30-60 min, 4 °C). Finally, cells were washed twice in Permeabilization 
Buffer and resuspended in 150 μl FACS buffer.  
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Acquisition and Data Analysis 
For cell number quantification, 104 FACSuite FC Beads (BD) were added per sample prior to acquisition. 
Samples were acquired in FACS Calibur or FACS Verse (both BD). FACS data were analyzed using FlowJo 
7.6.5 software (TreeStar). 
Cell Sorting 
Isolated splenocytes pooled from 2-4 mice were suspended in 2-4 ml RPMI, filtered through 100 μm filter 
and sorted to GFP+ and GFP- cell using a MoFlo XDP cell sorter (Beckman Coulter).  
2.2.3 Cell Culture 
T cell Purification 
For purification of T cells from total splenocytes, MagCellect Cell Selection Kit for mouse naïve CD4+ 
T cells (R&D Systems) was used according to manufacturer’s instructions. 
Suppression Assay 
105 Teff, 5 x 104 Treg and 2 x 105 irradiated (50 Gy) splenocytes per well were plated in 96-well round-
bottom plates in a total volume of 200 μl complemented RPMI in triplicates. Anti-CD3e (BD) (0.5 μg/ml) 
was added. After a culture period of 48 hours, 1 μCi 3H-labeled thymidine (PerkinElmer) was added per 
well. Samples were harvested 16 hours later and tritium incorporation was measured on a Matrix 9600 
Direct Beta Counter (Packard). 
2.2.4 RNA Techniques 
RNA extraction & Reverse Transcription 
Total RNA was isolated with TRI Reagent (Sigma-Aldrich). Whole tissue or cells were placed in 1 ml TRI 
Reagent and stored at -20 oC until RNA extraction.  For RNA extraction, 200 μl of chloroform were added; 
samples were vortexed vigorously and centrifuged at 19000 rcf for 15 min at RT. The aqueous phase was 
removed and RNA was precipitated with 500 l of isopropanol. RNA was washed in 1 ml of 75 % ethanol 
and finally dissolved in RNase-free water. cDNA was generated from 1 μg total RNA using the Verso 
cDNA Kit (Thermo Fisher Scientific), according to the manufacturer´s instructions. 
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Quantitative Real-Time PCR 
Sense and antisense primers in combination with FAM/TAMRA TaqMan fluorescent probes (all from 
Metabion) were used for quantitative PCR analysis. Where possible, the primer/probe sequence 
combinations spanned contact sequences of subsequent exons. For amplification, the Absolute QPCR 
mix was used (ABgene). Each reaction was run in triplicate on a 7900HT Fast Real-Time PCR System 
(Applied Biosystems) and was normalized to housekeeping gene GAPDH transcripts. Primary data was 
analyzed using Gene-Amp SDS 2.3 software (Applied Biosystems). 
2.2.5 Fluorescent Immunohistochemistry 
Mice were anesthetized and perfused transcardially through left ventricle with 20 ml cold PBS and 20 ml 
4 % paraformaldehyde (PFA) in PBS. Organs were dissected and stored in the same fixative overnight at 
4 °C, washed with PBS, and finally kept at 4 °C in 25 % sucrose in PBS solution. 
Tissues were embedded in Tissue-Tek O.C.T Compound (Sakura) and frozen in -20 oC. Frozen tissue 
sections (10-20 μm) were performed using Cryostat CM3050 S (Leica). Tissue sections were thawed and 
incubated with blocking buffer for 1-2 hours at RT. Next, incubation with primary antibody (1:200) in 
staining buffer was performed for 1-2 hours at RT or overnight at 4 °C and the sections were washed 3 
times with wash buffer. Incubation with secondary antibody (1:200 - 1:400) in staining buffer followed 
for 1-2 hours at RT in the dark, before sections were eventually washed 3 times with wash buffer and 
embedded in Gel Mount Aqueous Mounting Medium (Sigma-Aldrich). Images were acquired on a SP5 
confocal microscope (Leica), using 20x air-immersion (N.A. 0.70) or 63x oil-immersion (N.A. 1.4) 
objective. Images were processed using Image J (NIH) and Photoshop CS5 software (Adobe Systems). 
2.2.6 Intravital two-photon Imaging 
Image Acquisition 
Time-lapse two-photon laser-scanning microscopy was performed using a SP2 confocal microscope 
(Leica) equipped with a 10 W Millenia/Tsunami laser (Newport). The excitation wavelength was tuned to 
880 nm and routed through a 20x water-immersion objective (N.A. 0.95, Olympus) or 25x water-
immersion objectives (N.A. 0.95, Leica). 1x or 1.5x zoom was used and 40-80 μm z-stacks were acquired 
with 3-6 μm z-step. The acquisition rate was set to 25.219 s interval time and images were line-averaged 
twice. The acquisition time was approximately 1 hour per experiment. Fluorescent signals were detected 
using non-descanned photomultiplier tube detectors (Hamamatsu) equipped with 440/40 nm (for 
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detection of second harmonic), 525/50 nm (for detection of GFP and Alexa Fluor 488), 579/34 nm (for 
detection of tetramethylrhodamine dextran), 630/69 nm (for detection of dsRedII), and 685/40 nm (for 
detection of Alexa Fluor 647 and 680) band-pass filters (Semrock). 
Animal Preparation 
Animals were anesthetized by intraperitoneal injection of fentanyl/midazolam/medetomidine (50 μg/kg, 
5 mg/kg, and 500 μg/kg bodyweight, respectively) mix in PBS, tracheally intubated and ventilated with 
1 % isoflurane. Animals were placed on custom-designed microscope stage (Bartholomaus, 2011) and 
body temperature was regulated at 36.5 - 37.5 °C by using a heating pad and temperature sensor. 
Electrocardiogram and physiological parameters, such as concentrations of inspiratory and expiratory 
gases and ventilation pressure, were constantly monitored and recorded during imaging. 
Spinal cord Imaging 
For spinal cord imaging, a spinal cord window was prepared at level thoracic-12 / lumbar-1. After midline 
skin incision, the paravertebral musculature was detached from the spine and 3 successive spine discs 
were fixed to reduce breathing and heart beating artifacts. Laminectomy was performed on the middle 
spine disc using a dental drill (FOREDOM). Agarose ring was mounted around the spinal cord window to 
retain the buffer in which water objective was embedded. 
Local Injections in Imaging Window 
In some experiments, fluorescent conjugated dextran was injected into the spinal cord meninges to 
visualize local APC. A microcapillary (13 μm tip diameter, Biomedical Instruments) was used for injection 
in the subarachnoid space. The capillary was inserted, using a microcapillary manipulator (Luigs & 
Neumann), through a hole (app. 20 μm diameter) created by applying shortly high-energy laser on the 
arachnoidea. Fluorescent dextran conjugate (10 ng/μl) was injected by CellTram vario (3-4 μl) 
(Eppendorf). 
Image analysis 
Time-lapse images were acquired using Leica LCS software (Leica), and subsequently processed and 
analyzed by ImageJ (NIH). To obtain two-dimensional movies, a Gaussian blur filter was applied and 
maximum intensity z-projections were made. In some videos, the contrast was adjusted by liner 
rescaling, and the noise was removed additionally using a median filter. The position of T cells in the two-
dimensional space was analyzed using Imaris software (Bitplane). Cell trajectories and motility 
parameters were calculated from the obtained position coordinates using Excel (Microsoft). Trajectory 
MATERIAL & METHODS 
40 
 
lines were drawn based on the obtained coordinate information. The instantaneous T cell velocity was 
calculated by combining the cell coordinates with the time interval of imaging (25.219 sec). The average 
velocity per T cell was the average of the instantaneous velocity values. The linearity index is defined as 
the sum of total displacement divided by the path length of a T cell (Bartholomaus, 2011). A cell was 
considered to be in stationary phase when its average velocity for three frames (75.66 sec) was less than 
3 μm per min. Treg/Teff – APC and Treg – Teff contacts were analyzed manually and all of the physical 
interactions between Treg, Teff and labeled meningeal APCs in the three-dimensional volume were 
defined as contacts.  
2.2.7 Statistical Analysis 
The statistical evaluation was performed using Prism software (GraphPad). A nonparametric t-test 
(Mann-Whitney) for one pair and one-way ANOVA (Kruskal Wallis test, – Dunn’s multiple comparison 
test) or two-way ANOVA (Bonferonni post test) for more than one pair, were used. In addition, survival 
curves were analyzed by Log-rank (Mantel-Cox) test. P<0.05 was considered significant. “n.s.” indicates 
no significance. 
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RESULTS 
3.1 Treg Depletion during aEAE 
3.1.1 Increased Treg Frequency in the CNS of Mice with aEAE during Recovery 
Treg have been reported to accumulate in the CNS of mice with aEAE, paralleling the recovery from the 
disease (Korn et al., 2007; McGeachy et al., 2005; O'Connor et al., 2007). To confirm these findings, a 
time-kinetic experiment analyzing Treg frequencies in peripheral immune tissues and the CNS was 
performed. Foxp3-GFP.KI B6 mice were immunized with MOG35-55 in CFA and the frequency of Treg cells 
was assessed during different phases of the disease (Fig. 3.1.1 a) using flow cytometry. In agreement 
with the aforementioned studies, Treg were present in the spinal cord throughout the course of EAE, but 
their frequency was significantly increased during the recovery phase. In contrast, Treg proportions in 
draining inguinal and axillary lymph nodes (LN) remained unaltered (Fig. 3.1.1 b,c). 
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Figure 3.1.1 Treg accumulation in the CNS during recovery from EAE. Foxp3-GFP.KI B6 mice were immunized with 
MOG35-55 in CFA. (a) Mean clinical score (± s.e.m.) following immunization and timepoints (onset, peak and 
recovery) were mice were sacrificed (n=5 mice) (b) Mean frequency (+ s.e.m.) of GFP+ in CD4+ T cells in pooled 
inguinal and axillary lymph nodes (LN, purple line) and spinal cord (orange line) (n=3 mice per group, representative 
data from two independent experiments. **P<0.01, 2way ANOVA between onset, peak and recovery). (c) 
Representative flow cytometry plots of CD4+ gated lymphocytes. Treg population and its percentage within the 
CD4
+
 compartment are indicated. 
Additionally, infiltration of Treg into the spinal cord during EAE and their enhanced frequency during 
recovery was confirmed by confocal microscopy of spinal cord sections (Fig. 3.1.2).  
In summary, the accumulation of Treg in the CNS during recovery from EAE indicates a possible role for 
this T cell subset in disease remission. 
 
Figure 3.1.2 Treg accumulation in spinal cord during different phases of EAE. Foxp3-GFP.KI B6 mice were 
immunized with MOG35-55 in CFA and sacrificed at day 1 (onset), day 3-5 (peak) or day 7-10 (recovery) post EAE 
onset. Spinal cord cryosections were stained with anti-CD4 Ab (red). Foxp3+ cells express GFP and are depicted in 
green. Images were acquired by confocal microscopy. (a), (b), (c) Representative panoramic pictures of spinal cord 
cross sections at the indicated disease phase, composed by approximately 10 pictures acquired with 20x objective 
lens (scale bar: 200 μm). (d), (e), (f) Magnified pictures of the indicated regions of the spinal cord cross sections (a), 
(b) and (c), acquired with 63x objective lens (scale bar: 50 μm). 
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3.1.2 Acute Treg Depletion Prevents Recovery and Leads to Fatal EAE 
Targeted ablation of the Treg population could elucidate the role of Treg during the recovery phase of 
EAE. As discussed before (see Introduction – Treg in EAE), although treatment with anti-CD25 Ab has 
been performed in several studies, it does not result in specific elimination of Treg, as CD25+ Teff are also 
affected. In order to target Treg efficiently, the transgenic DEREG mice were selected for this study, as 
they express a diphtheria toxin (DTx) receptor-enhanced GFP fusion protein, under the control of the 
foxp3 gene locus, permitting specific depletion of Treg by treatment with DTx (Lahl et al., 2007). 
Therefore, DEREG and non-transgenic littermate control (NTL) B6 mice were immunized with MOG35-55 in 
CFA and treated with DTx or PBS four days post onset.  
The efficiency of the Treg ablation in peripheral immune organs and the CNS was tested by flow 
cytometry two days after the treatment. Indeed, staining for Foxp3 revealed that Treg population was 
almost completely lost in DTx-treated DEREG mice as compared to the control animals (Fig. 3.1.3 a,b). 
 
Figure 3.1.3 Prevention from recovery and exacerbation of EAE after efficient Treg depletion at the peak of the 
disease. DEREG and NTL mice were immunized with MOG35-55 in CFA and treated with DTx or PBS four days after 
the onset of EAE. (a) Representative flow cytometry plots of CD45
+
CD4
+
 gated lymphocytes isolated from LN and 
spinal cord of DEREG mice sacrificed two days after DTx or PBS treatment. Treg population and its percentage 
within the CD4
+
CD45
+
 compartment are shown. (b) Mean frequency (+ s.e.m.) of Foxp3
+
 in CD45
+
CD4
+
 T cells in 
peripheral immune tissues and the CNS of DEREG mice, two days after the DTx/PBS treatment (n=3-4 mice per 
group, representative data from three independent experiments) (c) Mean clinical score (+ s.e.m.) of mice 
following immunization and DTx or PBS treatment (day 4 post EAE onset). (n=5-7 mice per group, representative 
data from two independent experiments. *P<0.05, **P<0.01, ****P<0.0001, 2way ANOVA between DEREG DTx 
and DEREG PBS groups) 
Next, immunized and treated mice were monitored daily for clinical score to assess the effect of Treg 
depletion on EAE pathogenesis. DTx-treated DEREG mice not only showed no recovery from the disease, 
but also developed severe and, eventually, fatal EAE. In sharp contrast, the PBS-treated DEREG, as well 
RESULTS 
44 
 
as DTx and PBS-treated NTL mice, partially recovered from EAE (Fig. 3.1.3 c). These finding suggests that 
Treg are essential for recovery from aEAE.  
3.1.3 Treg Depletion Effect on Teff 
The dramatic outcome of Treg ablation during the course of EAE raised the question of how the disease 
exacerbation is mediated. As discussed earlier, Treg are believed to directly suppress Teff. Therefore, the 
effect of Treg depletion on Teff numbers and phenotype was examined by flow cytometry. Interestingly, 
lymph nodes and spinal cord of Treg-depleted mice exhibited significantly increased numbers of Teff 
compared to control mice (Fig. 3.1.4 a). In addition, the activation status of Teff was tested by staining 
with CD44 and CD25. Surprisingly, no difference was observed in the percentage of activated Teff 
(defined as CD44highCD25+) in periphery as well as the CNS of DTx-treated compared to PBS-treated 
DEREG mice (Fig. 3.1.4 b). 
 
Figure 3.1.4 Increased numbers, but not higher activation status, of Teff after Treg depletion at the peak of EAE. 
DEREG B6 mice were immunized with MOG35-55 in CFA and treated with DTx or PBS four days after the EAE onset. 
Two days later they were sacrificed and lymphocytes were isolated from LN and spinal cord and analyzed by flow 
cytometry. (a) Mean absolute numbers (+ s.e.m.) of Teff (CD45
+
CD4
+
Foxp3
-
 cells) (n=8 mice per group, pooled data 
from three independent experiments). (b) Mean frequency (+ s.e.m.) of activated (CD44
high
CD25
+
) Teff in DTx- and 
PBS-treated mice (n=6-7 mice per group, pooled data from two independent experiments). (*P<0.05, **P<0.01, t-
test) 
Next, the cytokine-producing profile of Teff was examined. Notably, Treg depletion led to increased 
frequency of IFNγ+ Teff in the LN, but not in the spinal cord (Fig. 3.1.5 b). In contrast, the fraction of IL-
17+ Teff was comparable in Treg-depleted and Treg-intact mice, both in LN and spinal cord (Fig. 3.1.6 b). 
Nevertheless, DTx-treated mice displayed augmented absolute numbers of these proinflammatory 
cytokine-producing Teff. In fact, significantly more IFNγ-producing Teff were found in LN and spinal cord 
of DTx-treated DEREG mice (Fig. 3.1.5 a). This finding was corroborated by real-time PCR analysis, which 
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showed significantly elevated IFNγ mRNA levels in LN of Treg-depleted mice (Fig. 3.1.5 c). Similarly, more 
IL-17+ Teff were observed in the spinal cord of Treg-depleted mice (Fig. 3.1.6 a), paralleled by increased 
IL-17 mRNA levels (Fig. 3.1.6 c). 
 
In summary, the exacerbated EAE pathology observed in Treg-depleted mice could be attributed to the 
elevated numbers of Teff both in LN and spinal cord, leading to enhanced inflammation as indicated by 
the increased levels of IFNγ and IL-17. 
Figure 3.1.5 Increased numbers of IFNγ-producing 
Teff and eleveated IFNγ mRNA levels after Treg 
depletion at the peak of EAE. DEREG mice were 
immunized with MOG35-55 in CFA and treated with DTx 
or PBS four days after the EAE onset. Two days later 
they were sacrificed and lymphocytes were isolated 
from axillary and inguinal lymph nodes (LN) and spinal 
cord and analyzed by flow cytometry (a,b) or total 
mRNA was extracted from LN and spinal cord (c). (a) 
Mean absolute numbers (+ s.e.m.) of 
CD45+CD4+Foxp3-IFNγ+ cells (b) Mean frequency (+ 
s.e.m.) of IFNγ+ in CD45+CD4+Foxp3- cells (n=6-7 mice 
per group, pooled data from two independent 
experiments). (c) Expression of IFNγ (mRNA relative 
to GAPDH quantified by real-time PCR (n=5-7 mice 
per group). (*P<0.05, **P<0.01, t-test) 
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3.1.4 Treg Depletion Effect on Macrophages 
Treg can possibly exert their suppressive capacity also on cells of the innate immune system. 
Macrophages are not only potent APC, but also main mediators of the disease pathology. Therefore, the 
macrophage numbers in EAE-affected Treg-depleted mice were assessed by using flow cytometry. 
Significantly elevated numbers of macrophages were found in the spinal cord infiltrates of DTx-treated 
compared to control animals, while their numbers in LN remained similar(Fig. 3.1.7 a). 
Figure 3.1.6 Increased numbers of IL-17-producing 
Teff and eleveated IL-17 mRNA levels after Treg 
depletion at the peak of EAE. DEREG mice were 
immunized with MOG35-55 in CFA and treated with DTx 
or PBS four days after the EAE onset. Two days later 
they were sacrificed and lymphocytes were isolated 
from axillary and inguinal lymph nodes (LN) and spinal 
cord and analyzed by flow cytometry (a,b) or total 
mRNA was extracted from LN and spinal cord (c). (a) 
Mean absolute numbers (+ s.e.m.) of 
CD45+CD4+Foxp3-IL-17+ cells (b) Mean frequency (+ 
s.e.m.) of IL-17+ in CD45+CD4+Foxp3- cells (n=6-7 mice 
per group, pooled data from two independent 
experiments). (c) Expression of IL-17 (mRNA relative 
to GAPDH quantified by real-time PCR (n=5-7 mice 
per group). (*P<0.05, **P<0.01, t-test) 
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Figure 3.1.7 Increased numbers of CD11b+ macrophages after Treg depletion at the peak of EAE. DEREG mice 
were immunized with MOG35-55 in CFA and treated with DTx or PBS four days after the EAE onset. Two days later 
they were sacrificed and lymphocytes were isolated from axillary and inguinal lymph nodes (LN) and spinal cord 
and analyzed by flow cytometry. (a) Mean absolute numbers (+ s.e.m.) of macrophages (CD45+CD11b+ cells) (n=8 
mice per group, pooled data from three independent experiments) (b) Mean frequency (+ s.e.m.) of CD86
+
 and 
MHC II
+
 in CD45
+
CD11b
+
 cells in DTx-(red bars) and PBS-treated (blue bars) mice (n=8 mice per group, pooled data 
from three independent experiments). (c) Mean frequency (+ s.e.m.) of IFNγ
+
 and TNFα
+
 in CD45
+
CD11b
+
 cells in 
DTx-(red bars) and PBS-treated (blue bars) mice (n=3-4 mice per group). (d) Mean frequency (+ s.e.m.) of CD206
+
 in 
CD45+CD11b+ cells (n=8 mice per group, pooled data from three independent experiments). (*P<0.05, **P<0.01, t-
test) 
Next, the effect of Treg depletion on the macrophage phenotype was examined. Surprisingly, ablation of 
Treg did not lead to changes in the activation status of macrophages, as shown by staining for CD86 and 
MHC II (Fig. 3.1.7 b), or their cytokine-producing capacity, including IFNγ and TNFα (Fig. 3.1.7 c). 
However, intriguingly, LN from DTx-treated DEREG mice showed significantly reduced frequency of 
mannose-receptor-expressing (CD206+) macrophages (Fig. 3.1.7 d). CD206+ is considered to be a surface 
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marker of the alternatively-activated macrophages (M2 macrophages), which have immunoregulatory 
functions (Sica and Mantovani, 2012b).  
Thus, these findings indicate that Treg depletion leads to more severe EAE pathology on the one hand by 
increasing the numbers of macrophages found in the CNS infiltrates and on the other hand by decreasing 
the frequency of regulatory macrophages in peripheral LNs. 
Finally, the enhanced accumulation of Teff and macrophages in spinal cord of Treg-depleted mice was 
confirmed by immunohistochemistry. Indeed, spinal cord sections from DTx-treated DEREG mice 
displayed highly increased numbers of infiltrating Teff and macrophages compared to PBS-treated 
animals (Fig. 3.1.8) 
 
Figure 3.1.8 Increased numbers of Teff and macrophages in spinal cord after Treg depletion at the peak of EAE.  
DEREG mice were immunized with MOG35-55 in CFA and treated with DTx or PBS four days after the EAE onset. Two 
days later they were sacrificed and spinal cord cryosections were prepared and stained with anti-Foxp3 (green), 
anti-CD4 (red) and anti-CD11b Ab (grey). Images were acquired by confocal microscopy. (a), (d) Representative 
panoramic pictures of spinal cord cross sections from mice treated with DTx (a) or PBS (d), composed by 
approximately 10 pictures acquired with 20x objective lens (scale bar: 200 μm). (b), (c), (e), (f) Magnified pictures of 
the indicated regions of the spinal cord cross sections (a) and (d), acquired with 63x objective lens (scale bar: 50 
μm). 
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In summary, Treg infiltrated the CNS during aEAE and their levels were enhanced during recovery from 
the disease. Selective depletion of Treg at the peak of EAE prevented recovery and led to severe 
exacerbation of the disease, characterized by enhanced numbers of IFNγ- and IL-17-producing Teff both 
in draining LN and the CNS, as well as elevated numbers of macrophages in the CNS. In total, these 
findings suggest that Treg can mediate recovery from EAE by controlling Teff and macrophage in the 
draining LN or the CNS, or both. 
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3.2 Visualizing the Function of Treg in the CNS during aEAE 
Intravital two-photon imaging is a powerful tool to visualize cell motility and interactions in vivo. This 
technique has been used in the last few years mainly in pEAE models, to elucidate T cell migration into 
the CNS and their subsequent reactivation (Bartholomaus et al., 2009; Kawakami et al., 2012; Pesic et al., 
2013). Although Treg function in peripheral immune organs has been assessed using in vivo or ex vivo 2-
photo imaging (Mempel et al., 2006; Tang et al., 2006), little is known about their locomotion and 
function within the CNS during EAE. 
3.2.1 Teff and Treg Motility and Contacts with APC in the CNS during aEAE 
As shown in the previous section, Treg are constantly present in the CNS of mice during EAE. However, 
their frequency is highly increased during recovery from the disease, suggesting that CNS-infiltrating Treg 
could contribute to amelioration of EAE. To shed light on the function of Treg within the inflamed CNS 
tissue, intravital two-photon imaging in the spinal cord meninges was performed. To visualize both Treg 
and Teff, Foxp3-GFP.KI mice, in which Treg express GFP, were crossed to T-Red mice, whose T cells 
express the red fluorescent protein dsRedII. T-Red x Foxp3.GFP.KI mice were immunized with MOG35-55 in 
CFA and intravital two-photon imaging in the CNS was carried out at the onset, peak and recovery. Taken 
that perivascular and meningeal APC are not only necessary for T cell reactivation within the CNS by cell-
to-cell contact (Lodygin et al., 2013; Pesic et al., 2013), but also possible targets of Treg-mediated 
suppression mechanism, they were also visualized by injection of fluorescent-labeled Dextran in the 
subarachnoid space. Subsequently, semi-automated tracking of both Teff and Treg was performed in the 
acquired videos, allowing the calculation of motility parameters, including average track velocity, 
linearity index and stationary phase (see Material and Methods). In addition, as CNS-infiltrating T cells 
are known to establish contacts with local APC in order to get reactivated, contact number and duration 
between T cells and labeled APC were analyzed. 
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Figure 3.2.1 Teff locomotion and contacts with APC in spinal cord meninges during aEAE. T-Red x Foxp3-GFP.KI 
mice were immunized with MOG35-55 in CFA and intravital two-photon imaging was performed in the spinal cord 
meninges at onset, peak and recovery. Local APC were labeled by injection of Dextran-Alexa Fluor 680 in the 
subarachnoid space. (a) Trajectories (white lines) of dsRedII
+
 Teff overlaid with snapshots from representative 
videos. One representative out of three independent experiments per disease stage is shown (red: Teff, grey: APC, 
scale bar: 30 μm) (b) Superimposed trajectories of Teff movements during onset, peak and recovery. Timepoints 
with contacts with APC are indicated in red. One representative out of three independent experiments per disease 
stage is shown. (c) Average velocity, (d) linearity index, (e) stationary phase (+ s.e.m.) of Teff and (f) contact 
duration with APC during onset, peak and recovery (pooled data from three independent experiments. *P<0.05, 
***P<0.001, 1way ANOVA, Kruskal Wallis test – Dunn’s multiple comparison test). (g) Scattered plot of Teff-based 
contacts with APC where each dot represents a single Teff plotted for the number of contacts per hour and average 
duration of contacts (pooled data from three independent experiments). 
Initially, the locomotion of Teff, as well as their contacts with APC between the different phases of EAE 
were compared, as they could be affected by the differential presence of Treg in the CNS. Surprisingly, 
the trajectories of Teff did not show major changes during different disease stages (Fig. 3.2.1 a,b). In 
detail, their velocity was only marginally decreased at the peak, in agreement with the increased 
percentage of stationary phase at this timepoint (Fig. 3.2.1. c,e). However, these differences were not 
depicted in the linearity index, which remained unaltered as the disease progressed (Fig. 3.2.1. d). 
Importantly, the duration and number of Teff – APC contacts were indistinguishable between the three 
phases of EAE (Fig. 3.2.1 f,g). 
Taken together, these observations indicate that Teff motility and contact with APC is not strongly 
affected neither by the frequency of Treg in the CNS, which is higher during recovery, nor by the changes 
in the inflammatory milieu during the three distinct phases of EAE. 
Next, to elucidate the function of Treg within the CNS, their motility pattern and contacts with local APC 
at the three phases of EAE were assessed, as APC can be targets of Treg-mediated suppression. Treg 
showed increased motility at the onset of the disease: their trajectories were more linear (Fig. 3.2.2 a,b), 
in agreement with higher linearity index (Fig. 3.2.2 d). In parallel, at this timepoint their velocity was 
higher (Fig. 3.2.2 c), while they also displayed significantly shorter stationary phase (Fig. 3.2.2 e). 
Additionally, Treg contacted APC for shorter time during this phase (Fig. 3.2.2 f). In sharp contrast, Treg 
are less motile at the peak of EAE, displaying decreased velocity and increased stationary phase (Fig. 
3.2.2 c,d,e). Moreover, Treg formed longer contacts with labeled APC during this phase (Fig. 3.2.2 f). 
Lastly, Treg showed intermediate motility and contact duration during recovery phase. 
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Figure 3.2.2 Treg locomotion and contacts with APC in spinal cord meninges during aEAE. T-Red x Foxp3-GFP.KI 
mice were immunized with MOG35-55 in CFA and intravital two-photon imaging was performed in the spinal cord 
meninges at onset, peak and recovery. Local APC were labeled by injection of Dextran-Alexa Fluor 680 in the 
subarachnoid space. (a) Trajectories (white lines) of GFP
+
 Treg overlaid with snapshots from representative videos. 
One representative out of three independent experiments per disease stage is shown (green: Treg, grey: APC, scale 
bar: 30 μm) (b) Superimposed trajectories of Treg movements during onset, peak and recovery. Timepoints with 
contacts with APC are indicated in green. One representative out of three independent experiments per disease 
stage is shown. (c) Average velocity, (d) linearity index, (e) stationary phase (+ s.e.m.) of Treg and (f) contact 
duration with APC during onset, peak and recovery (pooled data from three independent experiments. *P<0.05, 
**P<0.01, ***P<0.001, 1way ANOVA, Kruskal Wallis test – Dunn’s multiple comparison test). (g) Scattered plot of 
Treg-based contacts with APC where each dot represents a single Treg plotted for the number of contacts per hour 
and average duration of contacts (pooled data from three independent experiments). 
As discussed previously, a possible mechanism of Treg-mediated suppression is direct cell-to-cell contact 
with Teff. Therefore, Treg-Teff contacts within the CNS were analyzed and compared between the 
different phases of EAE. At the onset of the disease, Treg contacted Teff for shorter time compared to 
peak and recovery (Fig. 3.2.3 c). In parallel, Treg – Teff interactions were more numerous during this 
phase (Fig. 3.2.3 b,d). In contrast, Treg-Teff contacts lasted longer during peak and recovery (Fig. 3.2.3 c), 
while they appear to be less frequent (Fig. 3.2.3 b,d). Thus, on the one hand, these observations further 
support a restricted role for Treg at the onset of EAE. On the other hand, they indicate that Teff can be 
also a target for Treg-mediated suppression in the CNS. 
In total, provided that Treg suppress immune reactions by direct contact with APC, these findings 
suggest a limited role for Treg within the CNS during the onset of EAE, when higher motility and shorter 
contacts with APC were observed. On the opposite, Treg displayed decreased motility and prolonged 
interactions with APC at the peak, indicating that they could exert their suppressive function during this 
phase of the disease. 
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Figure 3.2.3 Contacts between Treg and Teff in spinal cord meninges during aEAE. T-Red x Foxp3-GFP.KI mice 
were immunized with MOG35-55 in CFA and intravital two-photon imaging was performed in the spinal cord 
meninges at onset, peak and recovery. (a) Trajectories (white lines) of GFP
+
 Treg overlaid with snapshots from 
representative videos. One representative out of three independent experiments per disease stage is shown 
(green: Treg, red: Teff, scale bar: 30 μm) (b) Superimposed trajectories of Treg movements during onset, peak and 
recovery. Timepoints with contacts with Teff are indicated in cyan. One representative out of three independent 
experiments per disease stage is shown. (c) Contact duration between Treg and Teff during onset, peak and 
recovery (pooled data from three independent experiments. ***P<0.001, 1way ANOVA, Kruskal Wallis test – 
Dunn’s multiple comparison test). (d) Scattered plot of Treg-based contacts between Treg and Teff where each dot 
represents a single Treg plotted for the number of contacts per hour and average duration of contacts (pooled data 
from three independent experiments). 
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3.2.2 Treg Depletion Effect on Teff Motility and Contacts with APC in the CNS 
Intravital two-photon imaging studies have shown that, in the absence of Treg, CD4+ T cells formed 
prolonged contacts with DC in lymph nodes (Tadokoro 2006, Tang 2006). In order to examine how the 
ablation of Treg can affect the motility pattern of Teff and their contacts with local APC within the CNS in 
aEAE model, T-Red mice were crossed to DEREG mice, which allow effective depletion of Treg by treating 
with DTx. Subsequently, T-Red x DEREG mice were immunized with MOG35-55 in CFA and treated with DTx 
or PBS on day 4 after the EAE onset. Two days after the treatment, intravital two-photon imaging was 
carried out in the spinal cord meninges. Local APC were again visualized by injection of fluorescent-
labeled Dextran in the subarachnoid space. 
Semi-automated cell tracking of the dsRedII+ Teff revealed that in the DTx-treated mice, Teff displayed 
more confined trajectories compared to the PBS-treated mice (Fig. 3.2.4 a,b). Indeed, analysis of the Teff 
tracks showed that, in the spinal cord of Treg-depleted mice, Teff moved significantly slower than in PBS 
control group (Fig. 3.2.4 c). In addition, the linearity index of Teff was decreased, while the stationary 
phase of the cells increased (Fig. 3.2.4 c,d). However, no difference was observed in the contact 
duration, or number, of Teff with APC between the two groups (Fig. 3.2.4 f,g). Thus, Treg depletion did 
not seem to affect the Teff-APC contacts in the CNS. Nevertheless, in DTx-treated mice, many Teff 
trajectories appeared to be stationary but not accompanied by contact with APC (Fig. 3.2.4 b left), 
indicating possible interactions either with non-labeled APC or other cell types or structures within the 
spinal cord meninges. 
In conclusion, Treg depletion led to decreased Teff motility without changing contact duration with APC 
within the CNS. These observations suggest that, on the one hand, the primary target of Treg-mediated 
suppression is not the APC, but the Teff; on the other hand, the site where Treg control the autoimmune 
response may not be within the CNS, but rather in the peripheral immune organs. Nonetheless, the 
possibility that Teff establish contacts with non-labeled APC or other cell types and structures within the 
CNS, in the absence of Treg, cannot be excluded. Alternatively, the decreased motility of Teff following 
Treg depletion could be attributed to the highly inflammatory environment in the spinal cord of DTx-
treated mice. 
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Figure 3.2.4 Effect of Treg depletion on Teff motility and contacts with APC in spinal cord meninges during aEAE. 
T-Red x DEREG mice were immunized with MOG35-55 in CFA and treated with DTx or PBS four days after the EAE 
onset. Two days later, intravital two-photon imaging was performed in the spinal cord meninges. Local APC were 
labeled by injection of Dextran-FITC in the subarachnoid space. (a) Trajectories (white lines) of dsRedII+ Teff 
overlaid with snapshots from representative videos. One representative out of three independent experiments per 
treatment condition is shown (red: Teff, grey: APC, scale bar: 30 μm) (b) Superimposed trajectories of Teff 
movements after DTx or PBS treatment. Timepoints with contacts with APC are indicated in red or blue, 
respectively. One representative out of three independent experiments per treatment condition is shown. (c) 
Average velocity, (d) linearity index, (e) stationary phase (+ s.e.m.) of Teff and (f) contact duration with APC after 
DTx or PBS treatment (pooled data from three independent experiments. **P<0.01, t-test). (g) Scattered plot of 
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Teff-based contacts with APC where each dot represents a single Treg plotted for the number of contacts per hour 
and average duration of contacts (pooled data from three independent experiments). 
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3.3 Treg in Spontaneous Opticospinal EAE 
3.3.1 Treg Frequency, Ag-specificity and Suppressive Capacity in OSE mice 
Spontaneous EAE (sEAE) models provide an ideal setup to examine disease triggers compared to induced 
EAE models, as they do not require inoculation with adjuvants or transfer of ex vivo stimulated T cells. 
The Opticospinal Spontaneous EAE (OSE) mouse is one of the sEAE models that were developed in our 
lab (Bettelli et al., 2006a; Krishnamoorthy et al., 2006). OSE mice develop sEAE with 50 % incidence, 
raising the question whether Treg contribute to the disease resistance in 50% of transgenic mice.  
In order to address this question, frequency and Ag-specificity of Treg in the spleen of sEAE-affected and 
resistant OSE mice were compared using flow cytometry. Interestingly, both sEAE-affected and resistant 
OSE mice harbored similar percentage of Treg within the CD4+ T cell compartment (Fig. 3.3.1 a left). 
Additionally, the frequency of MOG-specific (Vα.3.2+Vβ11+) Treg was not different in OSE mice with sEAE 
compared to healthy animals (Fig. 3.3.1. a right). 
 
Figure 3.3.1 Treg frequency, Ag-specificity and suppressive capacity in spleen of affected or resistant OSE mice. 
(a) Mean frequency (+ s.e.m.) of Foxp3+ in CD4+ T cells (left) or Vα3.2+Vβ11+ in Foxp3+CD4+ T cells (right) (n=8-11 
mice per group, pooled data from five independent experiments) (n.s. = not significant, t-test) (b) GFP+ and GFP- 
cells were isolated from splenocytes of affected or resistant OSE x Foxp3-GFP.KI mice (n=4 mice per group) and 
CD4+ T cells were purified. 105 Teff were cultured with or without 5 x 104 Treg in the presence of 2 x 105 irradiated 
syngeneic splenocytes as APC and anti-CD3e Ab. After 48 hours, 
3
H-labeled thymidine was added and its 
incorporation was measured 16 hours later. Mean [
3
H] incorporation is indicated as c.p.m. (+ s.e.m) in triplicated 
wells (n.s. = not significant, t-test between “+Treg from affected” & “+Treg from resistant groups”). 
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Next, the suppressive capacity of Treg from affected and resistant OSE mice was examined by co-
culturing Treg with Teff from both groups. Treg from both groups suppressed Teff proliferation to the 
same extent (Fig. 3.3.1 b).  
In summary, no difference was detected in the proportion, Ag-specificity and suppressive capacity of 
spleen-isolated Treg between affected and resistant OSE. Taken together, these results suggest that 
susceptibility of OSE mice to sEAE is correlated neither with reduced frequency and Ag-specificity, nor 
with defective suppressive function of peripheral Treg. 
3.3.2 MOG-specific Treg Accumulation in the CNS during sEAE 
As shown earlier, Treg accumulate in the CNS of MOG-immunized mice during the recovery phase (Fig. 
3.1.1). However, little is known about Treg frequencies in both the periphery and the CNS during sEAE. 
Therefore, a kinetic experiment analyzing the percentages of Treg in CD4+ T cell population in spleen and 
spinal cord of OSE mice by flow cytometry was performed. Interestingly, while Treg levels in the spleen 
of OSE mice were low, independently of the disease phase, Treg were abundant in the spinal cord 
already from the onset of sEAE. Importantly, the frequency of Treg in the spinal cord paralleled the 
clinical score of affected OSE mice (Fig. 3.3.2 a). In addition, while in spleen only around half of Treg 
express the transgenic MOG-specific TCR, most of the Treg infiltrating the spinal cord are expressing 
MOG-specific TCR (Fig. 3.3.2 b). Thus, the accumulation of MOG-specific Treg in the spinal cord of 
affected OSE mice indicates a possible role for this T cell subset in this sEAE model like MOG-induced 
EAE.  
 
Figure 3.3.2 MOG-specific Treg accumulation in the CNS during sEAE. OSE x Foxp3-GFP mice were sacrificed at 
different time points after the onset of sEAE and lymphocytes were isolated from spleen and spinal cord. (a) Mean 
clinical score (+ s.e.m., grey line) and mean frequency (+ s.e.m.) of Foxp3+ (GFP+) in CD4+ T cells (Treg) in spleen 
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(purple line) and spinal cord (orange line) (n=4-9 mice per time point). (b) Mean frequency  (+ s.e.m.) of 
Vα3.2+Vβ11+ in CD4+GFP+ T cells in spleen (purple line) and spinal cord (orange line) (n=4-9 mice per group). 
3.3.3 Chronic DTx Treatment in OSE x DEREG mice Increases sEAE Incidence 
Depletion of the Treg population in OSE mice could be used to evaluate the role of Treg in sEAE incidence 
and severity. For this reason, OSE mice were crossed with DEREG mice and OSE x DEREG mice were 
treated with DTx (or PBS as control) twice per week, starting from the age of 21 days - prior to the 
earliest onset of sEAE – until the age of 52 days (Fig. 3.3.3 a). During the five-week treatment period, the 
efficiency of Treg depletion was analyzed twice by quantification of CD4+GFP+ T cells in blood using flow 
cytometry. Indeed, GFP+ cell population was drastically reduced in the blood of DTx-treated mice (Fig. 
3.3.3 b). 
 
Figure 3.3.3 Increased sEAE incidence in chronically DTx-treated OSE x DEREG mice. (a) Schematic representation 
of experimental setup. Arrows indicate treatment with DTx (100 ng in 100 µl) or PBS (100 μl). Red asterisks indicate 
testing the efficiency of Treg-depletion in blood. (b) Representative flow cytometry plots of CD4
+
 gated 
lymphocytes isolated from blood of 28-days old OSE x DEREG mice. Treg population and its percentage within the 
CD4
+
 compartment are indicated. (c) Incidence of spontaneous EAE in DTx- (n=18) and PBS-treated (n=17), as well 
as untreated (n=27) OSE x DEREG mice (*P<0.05, Log-rang (Mantel-Cox) Test). (d) Mean clinical score (+ s.e.m.) in 
DTx- (n=12) and PBS-treated (n=5), as well as untreated (n=8) OSE x DEREG mice. (n.s. = not significant, 2way 
ANOVA between all groups) 
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Intriguingly, OSE x DEREG mice treated chronically with DTx showed significantly increased sEAE 
incidence compared to the PBS treated or untreated animals (Fig. 3.3.3 c), suggesting that Treg are 
necessary for preventing spontaneous disease. However, the mean clinical score of DTx-treated 
OSE x DEREG mice was similar to those of the control groups (Fig. 3.3.3 d), indicating that Treg depletion 
does not affect the sEAE severity.  
3.3.4 Effect of DTx Treatment on Splenocyte Composition and Cytokine 
Production 
In order to evaluate the effect of chronic DTx treatment on the immune system of OSE x DEREG mice, 
the splenocyte composition was examined by staining with cell lineage markers and analyzed using flow 
cytometry. No differences were observed in the percentages of CD4+ cells or dendritic (CD11c+) cells, 
while a marginal increase in frequencies of CD8+ cells and macrophages (CD11b+) was found in DTx-
treated mice. In contrast, B (B220+) and NK (NKp46+) cell frequencies were significantly reduced in 
spleens of DTx-treated mice (Fig. 3.3.4 a). 
 
Figure 3.3.4 Effect of chronic DTx treatment on splenocyte populations and cytokine-production profile in 
OSE x DEREG mice. OSE x DEREG mice were chronically treated with DTx or PBS (as shown in Fig. 3.3.3 a) and 
sacrificed after 5 weeks of treatment. Splenocytes were isolated and analyzed by flow cytometry. (a) Mean 
frequency (+ s.e.m.) of indicated immune cell populations in total splenocytes (n=5 mice per group). (b) Mean 
frequency (+ s.e.m.) of IFNγ+ or IL-17+ in CD4+Foxp3- T cells (n=3-4 mice per group). (*P<0.05, t-test) 
Next, the cytokine production of splenic Teff following chronic DTx treatment was assessed by flow 
cytometry. Interestingly, DTx treated OSE x DEREG mice showed significantly increased frequency of 
IFNγ+ Teff, as well as marginally elevated levels of IL-17+ Teff (Fig. 3.3.4 b). This finding suggests that Treg 
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depletion affects the cytokine production by splenic Teff, pointing again to a modulatory role of Treg in 
the spleen of OSE mice. 
 
3.3.5 Incomplete Treg Depletion after Chronic DTx Treatment 
The efficiency of Treg depletion by DTx treatment was initially tested by quantification of the GFP+ T cells 
in OSE x DEREG mice. However, Foxp3 staining revealed the unexpected presence of a significant 
proportion of Foxp3+GFP- Treg in mice treated chronically with DTx (Fig. 3.3.5 a).  In contrast, this 
population is absent in mice which received only a single injection of DTx (Fig. 3.3.5 b). The presence of 
Foxp3+GFP- Treg in OSE x DEREG mice can be attributed to downregulation of the transgene in a minor 
fraction of Foxp3+ cells. When OSE x DEREG mice are treated chronically with DTx, the Foxp3+GFP- Treg 
population presumably expands homeostatically, due to the complete and continuous absence of 
GFP+Foxp3+ Treg. Therefore, the aforementioned findings in the present section, from experiments 
where chronic DTx treatment was performed, should be interpreted carefully, as Treg were absent only 
in the initial phase of the treatment and not until the end of the experimental procedure. 
 
Figure 3.3.5 Incomplete Treg depletion after chronic treatment with DTx in OSE x DEREG mice. Representative 
flow cytometry plots of CD4+ gated lymphocytes isolated from inguinal lymph nodes of OSE x DEREG mice treated 
(a) for 5 weeks (as shown inf Fig. 3.3.3 a) or (b) one day with DTx or PBS. 
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DISCUSSION 
4.1 Treg Depletion during aEAE 
The role of Treg in various EAE models has been investigated in several studies, by following two main 
approaches: On the one hand, transfer of Treg has been shown to ameliorate EAE or enhance recovery 
from the disease in both active and passive EAE models (Fransson et al., 2012; Kohm et al., 2002; 
McGeachy et al., 2005; Mekala and Geiger, 2005; Stephens et al., 2009; Yu et al., 2005; Zhang et al., 
2004). On the other hand, ablation of Treg population has been attempted by different groups by 
treatment with anti-CD25 antibody and resulted in exacerbation of EAE (Gartner et al., 2006; McGeachy 
et al., 2005; Montero et al., 2004; Zhang et al., 2004). However, a major drawback of the latter approach 
is that CD25 is not a Treg-specific marker, but is also expressed by activated T cells. Thus, anti-CD25 
treatment could eliminate not only the Treg population, but also a crucial fraction of Teff, making the 
interpretation of these findings rather complicated. 
The generation of mice with Foxp3-dependent expression of diphtheria toxin receptor, such as DEREG 
(Lahl et al., 2007) and Foxp3-DTR (Kim et al., 2007), allows precise targeting and specific depletion of 
Treg. In these studies, the importance of Treg for the maintenance of immune homeostasis and 
prevention of autoimmunity throughout the lifespan was convincingly shown. Therefore, these mice 
appear to be ideal for evaluating also the contribution of Treg to suppression of EAE.  
Indeed, DEREG mice were used in the present study. Treatment with DTx was performed at the peak of 
the EAE (four days after the onset). This timepoint was chosen because first, as Treg frequency in the 
CNS of mice with EAE has been reported to be increased at the recovery from the disease (a finding 
confirmed in this study), ablation of Treg during this phase was of great interest. Second, depletion of 
Treg shortly before the onset of EAE did not affect the course of the disease (data not shown). Third, DTx 
treatment combined with CFA and PTx injection proved to have lethal effects (Meyer Zu Horste et al., 
2010). Interestingly, treatment of MOG35-55-immunized DEREG mice with DTx at the peak of EAE not only 
prevented recovery from the disease, but also led to exacerbated and, eventually, fatal EAE. This finding 
strongly suggests that an intact Treg population is indispensable for recovery from EAE. 
In order to identify the mechanism of EAE exacerbation following Treg depletion, EAE-affected DEREG 
mice were sacrificed two days after treatment with DTx or PBS, thus before the difference in their clinical 
score became prominent. As Teff are considered to be main targets of the Treg-mediated suppression 
(see 1.4.2), the effect of Treg depletion on numbers, activation status and cytokine production of Teff 
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population was investigated. Importantly, highly increased numbers of Teff were observed in axillary and 
inguinal lymph nodes (LN), the draining lymph nodes of the immunization site, as well as in the spinal 
cord of Treg-depleted mice. This could be attributed to either higher proliferation rate or enhanced 
migration of Teff in the absence of Treg. However, no difference in the frequency of proliferating (Ki-67+) 
Teff was found between DTx- and PBS-treated mice (data not shown). In addition, blood-circulating Teff 
from both DTx- and PBS-treated mice expressed similar levels of integrin α4 chain (data not shown), that 
together with β1 compose VLA-4, suggesting that the increased Teff numbers in the CNS were not a 
result of higher expression of this migratory molecule. In addition, Teff from Treg-depleted mice were 
expressing similar levels of activation markers, such as CD25 and CD44, compared to Treg-intact animals, 
indicating that Treg do not modulate the activation status of Teff. In contrast, the cytokine profile of Teff 
was altered in the absence of Treg. Indeed, more IFNγ+ Teff were detected in LN and spinal cord of Treg-
depleted mice, accompanied with augmented levels of IFNγ mRNA. In parallel, increase in IL-17+ Teff 
numbers and IL-17 mRNA levels was observed in the spinal cord of DTx-treated mice. In conclusion, 
specific depletion of Treg during EAE resulted in significantly elevated numbers of Teff and enhanced 
proinflammatory cytokine production by Teff, both in periphery and the CNS, which is highly likely to 
contribute to the exacerbated pathology that follows. 
Apart from Teff, macrophages are also possible targets of the Treg-mediated suppression, as they can act 
as APC (see Introduction – Treg Suppression Mechanisms). Therefore, the effect of Treg ablation on 
macrophage number and phenotype was examined. Notably, spinal cord infiltrates of Treg-depleted 
mice displayed higher numbers of macrophages, as early as two days after treatment with DTx. As 
macrophages are major mediators of EAE pathology, by damaging oligodentrocytes and myelin sheath or 
causing directly neuronal toxicity (Herz et al., 2010), their enhanced presence in the spinal cord can 
further confer to the increased disease severity following ablation of Treg. 
Macrophages can undergo two different forms of activation, resulting in distinct functional phenotypes: 
On the one hand, classical activation by TLR ligands and IFNγ leads to M1 phenotype, classified by the 
production of proinflammatory cytokines and reactive nitrogen and oxygen species that promotes Th1 
reactions. On the other hand, alternative activation by IL-4/IL-13 results in M2 phenotype, which is 
characterized by production of ornithine and polyamines through the arginase pathway, expression of 
mannose and galactose receptors and enhanced phagocytic capacity. While M1 macrophages are 
associated with promoting and sustaining of inflammation, M2 macrophages are considered to exert 
immunoregulatory functions (Sica and Mantovani, 2012a). Intriguingly, Treg-depleted mice showed 
decreased frequency of mannose-receptor (CD206) expressing macrophages in their LN. Therefore, this 
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observation indicates that Treg ablation could lead to diminished levels of M2-like macrophages in LN 
that could also contribute to the exacerbated pathology. In contrast, the expression of M1-related 
markers, including CD80/CD86, MHC II, IFNγ and TNFα, was not altered in macrophages from Treg-
depleted animals. Nevertheless, the possibility that the elevated number of macrophages observed in 
Treg-depleted mice could occur as a result of increased levels of cell debris cannot be excluded. 
However, the decreased frequency of mannose-receptor expressing macrophages in LN of these animals 
does not point to this direction, as M2 macrophages are implicated in clearance of dead cells. 
In summary, specific depletion of Treg at the peak of EAE prevented recovery and led to exacerbated 
and, eventually, fatal disease, underlying the protective role of Treg during EAE. Treg-depleted mice 
were found to have increased number of Teff in both LN and spinal cord, accompanied with elevated 
levels of proinflammatory cytokines, such as IFNγ and IL-17. In parallel, ablation of Treg led to higher 
numbers of macrophages in spinal cord infiltrates, combined with reduced frequency of M2-like 
macrophages in LN. Thus, during EAE, Treg can act on Teff, limiting their expansion and production of 
proinflammatory cytokines, as well as on macrophages, restricting their presence in the CNS and possibly 
promoting M2 phenotype in periphery. 
4.2 Visualizing the Function of Treg in the CNS during aEAE 
Although Treg have been in the focus of scientific research in the last decade, our knowledge on the 
mechanisms they use to suppress autoimmune responses is rather limited and derives mainly from in 
vitro studies. Moreover, whether Treg exert their suppressive function within the target tissue of the 
autoimmune response or in peripheral immune organs, has not been answered to date. Intravital two-
photon imaging allows visualization of direct cell-to-cell contacts of Treg with Teff or APC that could shed 
light on the in vivo function of Treg. 
An indispensable step for T cell activation is direct contact with an APC, which allows the productive 
recognition of the target antigen through the immune synapse (Henrickson and von Andrian, 2007). 
Specifically within the CNS, reactivation of T cells has been shown to occur via interaction with 
perivascular and meningeal APC and this procedure is a prerequisite for initiation of the autoimmune 
response (Kawakami et al., 2012; Lodygin et al., 2013; Pesic et al., 2013). Earlier reports using two-
photon microscopy have demonstrated that CD4+CD25- T cells established longer contacts with DC in 
lymph node in the absence of Treg (defined as CD4+CD25+ T cells), while in Treg-sufficient environment 
these contacts were inhibited (Tadokoro et al., 2006; Tang et al., 2006). In fact, the latter study was 
carried out in an autoimmunity setup, where imaging of islet-specific Teff cells and DC bearing antigens 
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derived from pancreas was performed in the pancreatic lymph nodes of non-obese diabetic mice. 
Therefore, Treg can suppress an autoimmune response in the draining lymph nodes of the target organ, 
by restricting prolonged interactions between Teff and DC. In contrast, direct cell-to-cell interactions 
between Treg and Teff (Tang et al., 2006) or CTL (Mempel et al., 2006), have been proven unnecessary 
for suppressing the immune reaction. 
In the present study, the motility pattern of Treg, as well as and their interactions with Teff and APC 
during the EAE course within the CNS, were examined. The higher velocity and linearity index of Treg at 
the onset, combined with shorter stationary phase as well as contacts with APC and Teff, strongly 
suggest a limited role for Treg at this phase of the disease. In contrast, Treg appeared to be slower, more 
confined and stationary at recovery and, mainly, at the peak of EAE, when they also displayed prolonged 
interactions with APC and Teff. These observations indicate that, firstly, Treg are likely to exert their 
suppressive function in the CNS predominantly at the peak of EAE. Secondly, since Treg formed stable 
contacts with APC, importantly of similar duration to Teff – APC contacts, local APC can be targets of 
their suppressive function. Unfortunately, in the experimental setup used, the distinction between 
relevant and irrelevant interactions is not possible, as the CNS-infiltrating T cells are polyclonal. This 
would require T cells of defined antigen-specificity, as well as APC loaded with known antigen. Thirdly, as 
Treg interacted also with Teff, the possibility that they can directly suppress Teff by cell-to-cell contact 
cannot be excluded. 
Since Treg frequency in the CNS increases during recovery from EAE, Teff motility pattern and contacts 
with APC were also assessed throughout the disease. Interestingly, velocity and linearity index of Teff did 
not show striking variations between the different phases of EAE. A previous study has demonstrated 
higher velocity during remission, in case of adoptive transfer of polyclonal Teff, and lower velocity during 
peak, when 2D2 Teff were transferred, although the linearity index values did not vary accordingly 
(Siffrin et al., 2010). However, these discrepancies could be attributed to the differences in the 
experimental models (aEAE versus pEAE) and the imaged region (spinal cord meninges versus brain 
stem). Nevertheless, while Teff appeared to be more stationary at the peak, the Teff – APC contact 
duration and frequency was undistinguishable between the three phases of EAE. Therefore, the 
enhanced presence of Treg in the CNS during recovery did not affect the motility pattern of Teff and 
their interactions with APC. Additionally, the behavior of Teff is similar to Treg in all the phases, 
suggesting that inflammatory status is most likely the reason for the slowing of Teff at the peak. 
As Treg depletion at the peak of EAE prevented recovery and increased dramatically the severity of the 
disease, the motility pattern of Teff and their interactions with APC following Treg ablation were 
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investigated. Intravital two-photon imaging in the spinal cord meninges, carried out two days after Treg 
depletion in mice with EAE, revealed decreased velocity and linearity index of Teff, combined with 
increased stationary phase. In other words, Teff were slower and more confined in the absence of Treg. 
Surprisingly, however, no difference was observed in the Teff – APC contact duration in the spinal cord 
meninges of Treg-deficient and Treg-intact mice. This finding indicates that preventing contacts between 
Teff and perivascular and meningeal APC is not the major mechanism that Treg use to suppress the 
ongoing inflammation in the CNS. Thus, the decreased motility of Teff following ablation of Treg 
population could be attributed to longer interactions between Teff and other cell types or structures in 
the CNS. For example, Th17 cells have been reported to contact neurons directly and cause axonal 
damage during EAE (Siffrin et al., 2010). Alternatively, the change in the Teff motility in the CNS of Treg-
depleted mice could occur due to the enhanced inflammation observed in these mice, characterized by 
higher levels of proinflammatory cytokines and increased numbers of macrophages in spinal cord. 
However, technical limitations of the experimental model and setup used in this study should be also 
taken into consideration during the interpretation of the results. For example, incomplete labeling of 
perivascular and meningeal APC cannot be excluded, as they are only visualized by incorporation of 
fluorescently-conjugated Dextran which is injected in the subarachnoid space prior to imaging. Thus, APC 
with lower phagocytic activity would not be visible. Moreover, in this model, Teff are polyclonal and not 
specific for a defined antigen. Therefore, the myelin-reactive Teff would be only a fraction of the CNS-
infiltrating Teff population, which means that an important percentage of the observed Teff – APC 
interactions can be unspecific. 
Nevertheless, CNS-infiltrating Treg have been demonstrated to be unsuccessful in suppressing MOG-
specific Teff isolated also from the CNS of mice with EAE (Korn et al., 2007). Therefore, a scenario where 
Treg do not suppress the ongoing inflammation within the CNS, but rather in peripheral immune organs, 
could also explain the undistinguishable Teff – APC contact duration and numbers in the spinal cord 
meninges during presence or absence of Treg. To answer this, intravital imaging in the inguinal and 
axillary lymph nodes, that drain the immunization site, or the cervical lymph nodes, that drain the CNS, 
should be performed. 
In summary, intravital two-photon imaging in the spinal cord meninges during different phases of EAE 
revealed increased motility of Treg, accompanied with shorter interactions with APC and Teff, at the 
onset. In contrast, Treg displayed lower motility and prolonged contacts with APC and Teff mainly at the 
peak of EAE, suggesting that they exert their suppressive function during this phase. Specific depletion of 
Treg at the peak resulted in decreased motility of Teff in the CNS, although the Teff – APC contact 
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duration and frequency was not affected. Therefore, either preventing interactions of Teff with CNS-
located APC is not a main mechanism that Treg use to suppress EAE or the control of the autoimmune 
response by Treg occurs in peripheral immune organs. 
4.3 Treg in Spontaneous Opticospinal EAE 
As discussed earlier, the primary function of Treg that has been described is the prevention of 
autoimmunity (Sakaguchi et al., 1995). In fact, patients suffering from IPEX syndrome, as well as scurfy 
mice, bear mutations in the Foxp3 gene that lead to the dysfunction of Treg (Bennett et al., 2001; 
Brunkow et al., 2001; Chatila et al., 2000). In addition, specific depletion of Treg in neonatal or adult mice 
leads to terminal multi-organ autoimmunity (Kim et al., 2007; Lahl et al., 2007). However, although IPEX 
syndrome patients, scurfy mice and Treg-depleted animals display severe autoimmune responses in 
several tissues, the CNS remains, intriguingly, spared.  
The factors that contribute to triggering of autoimmune responses can be better studied in spontaneous 
disease models, which are independent of injection of immune adjuvants. In a sEAE model of MBP-
specific TCR transgenic mice in RAG-1-deficient background, the susceptibility to spontaneous disease 
has been attributed to the lack of Treg, (Olivares-Villagomez et al., 1998). Importantly, adoptive transfer 
of Treg to those mice prevents the development of sEAE (Hori et al., 2002). Thus, Treg can protect the 
CNS from autoimmune attack, even in the presence of myelin-specific T cells.  
In the OSE mouse model, MOG-specific T cells and B cells cooperate to induce sEAE to 50% of the 
animals, with the remaining 50% being resistant to spontaneous disease. Therefore, the possible 
contribution of Treg in the resistance to sEAE was investigated. Initially, the frequency and Ag-specificity 
of Treg in the spleens diseased and resistant OSE mice were compared. Interestingly, both OSE mice with 
sEAE and healthy animals displayed similar frequency of Treg and MOG-specific TCR-expressing Treg. In 
addition, Treg from both sEAE-affected and resistant OSE mice showed undistinguishable suppressive 
capacity. These findings suggest that susceptibility of OSE mice to sEAE cannot be attributed to 
decreased Treg levels, differential Ag-specificity or impaired suppressive function of Treg in the 
peripheral immune organs.  
However, despite the low percentage of Treg in the peripheral immune organs of OSE mice (less than 3% 
of CD4+ T cells) independently of the disease status, increased Treg frequency (more than 20% of CD4+ 
T cells) was observed in the CNS of OSE mice with sEAE, already from the early phase of the disease. The 
percentage of Treg in the CNS infiltrates remained stable throughout the sEAE course, unlike the aEAE 
model where Treg are abundant in the CNS only during the recovery phase. Moreover, most of the CNS-
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infiltrating Treg express the MOG-specific transgenic TCR, in contrast to Treg in the periphery where only 
half of them are expressing TCRMOG. Therefore, the accumulation of MOG-specific Treg in the CNS of OSE 
mice during sEAE points to a role for Treg within the target organ in this model. 
Selective ablation of the Treg population in OSE mice could elucidate the role of Treg in incidence and 
severity of sEAE. To perform this, OSE mice were crossed to DEREG mice and OSE x DEREG mice were 
treated chronically with DTx or PBS for 5 weeks, starting from 3 weeks of age. Interestingly, the DTx-
treated mice developed EAE in higher incidence compared to the PBS-treated control group. However, 
no difference was observed in the disease severity between the two groups. Moreover, DTx-treated mice 
showed significantly higher levels of IFNγ-producing Teff in their spleens compared to the PBS-treated 
animals, while the frequency of IL-17-producing Teff was only marginally increased. These observations 
further support a protective role for Treg in OSE mice. Importantly, the increase in disease incidence, but 
not burden, in Treg-depleted OSE mice on the one hand suggests that Treg contribute to protection from 
sEAE and on the other hand indicates that Treg act rather in peripheral immune tissue, and not in the 
CNS, to control the autoimmune response. 
However, the chronic DTx-mediated depletion of Treg proved to be, unexpectedly, incomplete. While 
short-term treatment with DTx leads to efficient ablation of Foxp3+ cells, chronic treatment with DTx 
results in the expansion of a CD4+Foxp3+GFP- population that is resistant to the toxin, as these cells do 
not express the DTx receptor fused to GFP. These DTR-GFP- Treg, the numbers of which are negligible in 
untreated or single DTx-treated OSE x DEREG mice, could occur due to silencing of the transgene by few 
cells. The observed increase of this population could be a result of homeostatic expansion, in order to 
replace the continuously depleted DTR-GFP-expressing Treg population. Thus, the findings of the 
experiments where OSE x DEREG mice were treated chronically with DTx should be interpreted with 
caution, as these mice harbor a significant number of non-DTR-expressing Treg. The previously described 
increase in the sEAE incidence in DTx-treated OSE x DEREG mice could be attributed to the absence of 
Treg in the initial days of the experiment. Nevertheless, an expansion of DTR-GFP-Foxp3+ Treg was also 
documented in a recent study, where irradiated low-density lipoprotein receptor-deficient (Ldlr-/-) mice 
receiving DEREG bone marrow were chronically treated with DTx (Klingenberg et al., 2013). Despite the 
incomplete elimination of Treg using DTx treatment, highly increased proliferation of lymph node cells 
from mice treated with DTx versus PBS was observed in this study. Therefore, these newly expanded 
Treg may have less suppressive capability or harbor a different TCR repertoire, possibly reflecting that 
they are not fully differentiated Treg. 
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In order to overcome the problem of the inefficient Treg depletion after chronic treatment with DTx, 
other genetically modified mice with depletable Treg, such as the Foxp3-DTR knock-in mouse (Kim et al., 
2007), could be used. Alternatively, single treatment with DTx could be performed in OSE x DEREG mice 
with sEAE, to investigate the effect of short-term Treg depletion in disease severity. Nonetheless, the 
aforementioned findings suggest a protective role for Treg in the OSE mouse model. While the increase 
in sEAE incidence, but not severity, indicates that Treg contribute protection from the disease in the 
periphery, the enhanced presence of Treg in the CNS of affected OSE mice points also to a possible role 
within the target tissue. 
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ABBREVIATIONS 
aEAE  actively induced Experimental Autoimmune Encephalomyelitis 
APC  Antigen-Presenting Cell(s) 
BBB  Blood-Brain Barrier 
BCR  B Cell Receptor 
BSA  Bovine Serum Albumin 
CD  Cluster of Differentiation 
CFA  Complete Freund’s adjuvant 
CNS  Central Nervous System 
CSF  Cerebrospinal Fluid 
CTL  Cytotoxic T Lymphocyte(s) 
CTLA-4  Cytotoxic T Lymphocyte Associated Antigen 4 
DC  Dendritic Cell(s) 
DTR  Diphtheria Toxin Receptor 
DTx  Diphtheria Toxin 
EAE  Experimental Autoimmune Encephalomyelitis 
FACS  Fluorescence-Activated Cell Sorting 
FCS  Fetal Calf Serum 
FITC  Fluorescein Isothiocyanate 
Foxp3  Forkhead box P3 
GAPDH  Glyceraldehyde 3-Phosphate Dehydrogenase 
GFP  Green Fluorescent Protein 
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor 
HLA  Human Leukocyte Antigen 
HRP  Horseradish Peroxidase 
ICAM-1  Inter-Cellular Adhesion Molecule 1 
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IFNγ  Interferon Gamma 
Ig  Immunoglogulin 
IL  Interleukin 
i.p.  Intraperitoneal 
iTreg  Induced Regulatory T cell 
i.v.  Intravenous 
LFA-1  Lymphocyte Function-Associated Antigen 1 
LN  Lymph Nodes 
MBP  Myelin Basic Protein 
MHC  Major Histocompatibility Complex 
MOG  Myelin Oligodendrocyte Glycoprotein 
MS  Multiple Sclerosis 
NK  Natural Killer 
n.s.  Not Significant 
nTreg  Natural Regulatory T cell(s) 
OSE  Opticospinal Experimental Autoimmune Encephalomyelitis 
OVA  Ovalbumin 
PBMC  Peripheral Blood Mononuclear Cells 
PBS  Phosphate Buffered Saline 
PCR  Polymerase Chain Reaction 
PE  Phycoerythrin 
pEAE  Passively transferred Experimental Autoimmune Encephalomyelitis 
PerCP  Peridinin Chlorophyll A Protein 
PFA  Paraformaldehyde 
PLP  Proteolipid Protein 
PMA  Phorbol 12-Myristate 13-Acetate 
rcf  Relative Centrifugal Force 
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RFP  Red Fluorescent Protein 
RPMI  Roswell Park Memorial Institute 
RR  Relapsing-Remitting 
RT  Room Temperature 
sEAE  Spontaneous Experimental Autoimmune Encephalomyelitis 
s.e.m.  Standard Error of Mean 
TCR  T Cell Receptor 
Teff  Effector T cell(s) 
TGF-β  Transforming Growth Factor Beta 
TNFα  Tumor Necrosis Factor Alpha 
Treg  Regulatory T cell(s) 
VCAM-1 Vascular Cell Adhesion Molecule 1 
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